<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006352" GROUP_ID="SCHIZ" ID="132206090612024060" MERGED_FROM="" MODIFIED="2013-07-09 17:35:27 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2013-07-09 17:35:27 +0100" MODIFIED_BY="Claire Irving">
<TITLE MODIFIED="2012-05-09 13:47:56 +0100" MODIFIED_BY="Claire Irving">Fluphenazine (oral) versus placebo for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-07-09 17:35:27 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="EBA2E88E82E26AA20078D4E6D607135E" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Hosam</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Matar</LAST_NAME><POSITION>Surgical Trainee</POSITION><EMAIL_1>hematar@doctors.org.uk</EMAIL_1><EMAIL_2>hematar@hotmail.co.uk</EMAIL_2><MOBILE_PHONE>07826692764</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Trauma and Orthopaedics</DEPARTMENT><ORGANISATION>Northern General Hospital</ORGANISATION><ADDRESS_1>Herries Road</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S5 7AU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 7826692764</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-07-09 17:35:27 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="EBA2E88E82E26AA20078D4E6D607135E" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Hosam</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Matar</LAST_NAME><POSITION>Surgical Trainee</POSITION><EMAIL_1>hematar@doctors.org.uk</EMAIL_1><EMAIL_2>hematar@hotmail.co.uk</EMAIL_2><MOBILE_PHONE>07826692764</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Trauma and Orthopaedics</DEPARTMENT><ORGANISATION>Northern General Hospital</ORGANISATION><ADDRESS_1>Herries Road</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S5 7AU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 7826692764</PHONE_1></ADDRESS></PERSON><PERSON ID="EBA2E5B082E26AA20078D4E6AAEB7CC4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Muhammad Qutayba</FIRST_NAME><LAST_NAME>Almerie</LAST_NAME><POSITION>Academic Clinical Fellow</POSITION><EMAIL_1>qalmerie@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Surgery</DEPARTMENT><ORGANISATION>Leeds Teaching Hospitals NHS Trust Royal Infirmary</ORGANISATION><ADDRESS_1>Beckett Street</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS9 7TF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="47582939521085724166111208154807" ROLE="AUTHOR"><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Sampson</LAST_NAME><POSITION>Systematic Reviewer</POSITION><EMAIL_1>stephanie.sampson@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Jubilee Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441158231287</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-05-13 19:36:05 +0100" MODIFIED_BY="Tessa Jane Grant">
<UP_TO_DATE>
<DATE DAY="18" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2013-07-09 13:54:50 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-07-09 13:54:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>No new conclusions made to the review after results of 2012 update search added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-07-09 13:54:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Review update completed: seven new studies identified in update search, each of which was excluded with reasons. 'Summary of findings' table added to grade the quality of the evidence. New format 'Risk of bias' tables have been constructed, with new ratings applied.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-05-13 19:27:00 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-05-13 19:27:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>).</P>
<P>7 studies added to awaiting assessment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-10 12:18:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 15:49:17 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="4" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-04 15:17:33 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="15" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-15 15:15:17 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Contact Author details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-13 13:17:52 +0100" MODIFIED_BY="Bethany  L York">
<DATE DAY="25" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-06-17 15:04:46 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-06-17 15:04:46 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-06-17 15:04:35 +0100" MODIFIED_BY="[Empty name]">
<NAME>No internal sources of support provided</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-06-12 12:29:37 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-06-12 12:29:37 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>UK Cochrane Collaboration Programme Grant 2011; Reference number: 10/4001/15</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-07-09 14:30:15 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-07-09 13:58:38 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-05-13 19:28:22 +0100" MODIFIED_BY="[Empty name]">Oral fluphenazine versus placebo for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-07-09 13:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>Antipsychotic drugs are the first line and mainstay of treatment for schizophrenia. They help to effectively treat psychotic symptoms such as hearing voices and seeing things (hallucinations) and having strange beliefs (delusions). Fluphenazine was one of the first antipsychotics and has been available for around 50 years. Fluphenazine is inexpensive and in developing countries, may be one of the only drug treatments available. In most of Europe and North America, despite still being available, the arrival of newer antipsychotic drugs has reduced the use of fluphenazine and its market share. Fluphenazine has debilitating side effects, including: dizziness; movement disorders such as involuntary movements or spasms; shaking and tremors; inner restlessness and the inability to sit still; and problems with blood pressure, fever and muscle stiffness.</P>
<P>This review included seven studies and compared the effects of fluphenazine taken by mouth with placebo (&#8216;dummy&#8217; treatment).  In the main, the findings of the review support the widespread view that fluphenazine is a potent and effective antipsychotic but has considerable side effects, other antipsychotic drugs may well be preferable. Fluphenazine is an imperfect treatment with serious side effects, so other inexpensive antipsychotic drugs with fewer side effects may be better for people with schizophrenia. Despite this, fluphenazine has a low cost and is widely available, so is likely to remain one of the most widely used treatments for schizophrenia worldwide. However, some of fluphenazine's side effects could be expensive in terms of human suffering and personal cost of treatment. Even though fluphenazine has been used as an antipsychotic drug for decades, there are still a surprisingly small number of well-conducted studies measuring its effectiveness and potential to cause side effects. Future large-scale research should report on important outcomes such as improvement in mental health, relapse, hospital discharge and admission, levels of satisfaction with treatment and quality of life.</P>
<P>This plain language summary has been written by a consumer Ben Gray from RETHINK.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-07-08 16:19:16 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Fluphenazine is one of the first drugs to be classed as an 'antipsychotic' and has been widely available for five decades.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-06-18 14:42:28 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-06-18 14:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>We updated searches of the Cochrane Schizophrenia Group's trials register, which includes relevant randomised controlled trials from the bibliographic databases Biological Abstracts, CINAHL, The Central Register of Controlled Trials in <I>The Cochrane Library</I>, EMBASE, MEDLINE, PsycLIT, LILACS, PSYNDEX, Sociological Abstracts and Sociofile, 15 May, 2012. References of all identified studies were searched for further trial citations.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We sought all randomised controlled trials comparing oral fluphenazine with placebo relevant to people with schizophrenia. Primary outcomes of interest were global state and adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-08 16:19:16 +0100" MODIFIED_BY="[Empty name]">
<P>We inspected citations and abstracts independently, ordered papers and re-inspected and quality assessed trials. We extracted data independently. Dichotomous data were analysed using fixed-effect risk ratio (RR) and the 95% confidence interval (CI). Continuous data were excluded if more than 50% of people were lost to follow-up, but, where possible, mean differences (MD) were calculated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-07-08 16:19:12 +0100" MODIFIED_BY="[Empty name]">
<P>From over 1200 electronic records of 415 studies identified by our initial search and this updated search, we excluded 48 potentially relevant studies and included seven trials published between 1964 and 1999 that randomised 439 (mostly adult participants). No new included trials were identified for this review update. Compared with placebo, global state outcomes of 'not improved or worsened' were not significantly different in the medium term in one small study (n = 50, 1 RCT, RR 1.12 CI 0.79 to 1.58, <I>very low quality of evidence</I>). The risk of relapse in the long term was greater in two small studies in people receiving placebo (n = 86, 2 RCTs, RR 0.39 CI 0.05 to 3.31, <I>very</I> <I>low quality of evidence</I>), however with high degree of heterogeneity in the results. Only one person allocated fluphenazine was reported in the same small study to have died on long-term follow-up (n = 50, 1 RCT, RR 2.38 CI 0.10 to 55.72, <I>low quality of evidence</I>). Short-term extrapyramidal adverse effects were significantly more frequent with fluphenazine compared to placebo in two other studies for the outcomes of akathisia (n = 227, 2 RCTs, RR 3.43 CI 1.23 to 9.56, <I>moderate quality of evidence</I>) and rigidity (n = 227, 2 RCTs, RR 3.54 CI 1.76 to 7.14, <I>moderate quality of evidence</I>).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-03-14 10:19:36 +0000" MODIFIED_BY="[Empty name]">
<P>The findings in this review confirm much that clinicians and recipients of care already know, but they provide quantification to support clinical impression. Fluphenazine's global position as an effective treatment for psychoses is not threatened by the outcome of this review. However, fluphenazine is an imperfect treatment and if accessible, other inexpensive drugs less associated with adverse effects may be an equally effective choice for people with schizophrenia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-07-09 14:28:48 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<BR/>
</B>
</P>
<CONDITION MODIFIED="2013-07-08 16:18:45 +0100" MODIFIED_BY="[Empty name]">
<P>One in every 10,000 people per year is diagnosed with schizophrenia, with a lifetime prevalence of about 1% (<LINK REF="REF-Jablensky-1992" TYPE="REFERENCE">Jablensky 1992</LINK>). It often runs a chronic course with acute exacerbations and often partial remissions. Over the past few decades, a large body of evidence has accumulated linking excessive dopamine transmission to psychosis and more direct evidence emerges from neuro-imaging studies which showed an increased dopamine synthesis (<LINK REF="REF-Hietala-1995" TYPE="REFERENCE">Hietala 1995</LINK>; <LINK REF="REF-Lindstrom-1999" TYPE="REFERENCE">Lindstrom 1999</LINK>; <LINK REF="REF-Meyer-2002" TYPE="REFERENCE">Meyer 2002</LINK>), an exaggerated release of dopamine and a higher than normal levels of dopamine at baseline (<LINK REF="REF-Abi_x002d_Dargham-2000" TYPE="REFERENCE">Abi-Dargham 2000</LINK>; <LINK REF="REF-Gjedde-2001" TYPE="REFERENCE">Gjedde 2001</LINK>). The antipsychotic group of drugs with its anti-dopaminergic effects is the mainstay treatment for this illness (<LINK REF="REF-Dencker-1980" TYPE="REFERENCE">Dencker 1980</LINK>). These are generally regarded as highly effective, especially in controlling such symptoms as hallucinations and fixed false beliefs (delusions) (<LINK REF="REF-Kane-1986" TYPE="REFERENCE">Kane 1986</LINK>). Moreover, they seem to reduce the risk of acute relapse. A systematic review undertaken two decades ago also suggested that, for those with serious mental illness, stopping antipsychotics resulted in 58% of people relapsing, whereas only 16% of those who were still on the drugs became acutely ill within a one-year period (<LINK REF="REF-Davis-1986" TYPE="REFERENCE">Davis 1986</LINK>).</P>
<P>Schizophrenia usually begins in young adulthood and has a lifetime prevalence of about 1% irrespective of culture, social class and race. Schizophrenia is a chronic relapsing mental illness, characterised by symptoms such as hallucinations, delusions, disordered thinking, and emotional withdrawal. Antipsychotic drugs are effective for controlling florid symptoms such as hallucinations and delusions but are less effective for treating emotional withdrawal. Antipsychotics are associated with adverse effects such as movement disorders, and the overall cost of the illness to the individual, their carers and the community is considerable.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-06-18 15:06:36 +0100" MODIFIED_BY="[Empty name]">
<P>Fluphenazine, a phenothiazine derivative, was one of the first drugs to be classed as an 'antipsychotic' and was approved by the FDA in 1959. In Britain it was first used for the relief of anxiety. The American reports, however, were the first to indicate its value in psychotic illness (<LINK REF="REF-Darling-1959" TYPE="REFERENCE">Darling 1959</LINK>; <LINK REF="REF-Holt-1960" TYPE="REFERENCE">Holt 1960</LINK>). Fluphenazine has trifluoromethyl and piperazine groups which bring about increase in potency that in many pharmacodynamic properties may be about 40 times as potent as chlorpromazine. This is associated with a rapid and prolonged action, relatively little sedative activity and little or no increase in autonomic and haemodynamic effects.</P>
<P>Fluphenazine is an inexpensive and widely accessible antipsychotic drug that has been available to treat people with schizophrenia for five decades. In this review, for perhaps the first time, we objectively quantify the effects of oral administration of fluphenazine in comparison with placebo. It is indeed a potent antipsychotic but with considerable adverse effects. Other drugs may well be preferable.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fluphenazine is thought to elicit its antipsychotic effects via interference with central dopaminergic pathways and blocking receptors, particularly D2, in the mesolimbic zone of the brain. Extrapyramidal side effects are a result of interaction with dopaminergic pathways in the basal ganglia. As fluphenazine is not specific to one action within the body, it is known to cause adverse effects ranging from orthostatic hypotension as a result of its alpha adrenergic blocking activity to anticholinergic and extrapyramidal symptoms (tardive dyskinesia, pseudo-parkinsonism, dystonia, dyskinesia, akathisia). In addition, the use of fluphenazine has been associated with a potentially fatal disturbance of blood pressure, temperature and muscle control (neuroleptic malignant syndrome). As with all antipsychotic medications, fluphenazine is characterised by inter-individual variability in pharmacokinetics, most marked with the oral preparation. It is extensively metabolised, undergoing 'first pass' metabolism by the liver and is excreted in both the urine and faeces. Fluphenazine is highly protein-bound (greater than 90%) in plasma. With oral fluphenazine, peak plasma/serum levels are attained within a few hours. The serum half-life of it is approximately 15 hours. Fluphenazine crosses the blood-brain barrier, crosses the placenta easily and cannot be removed by dialysis (<LINK REF="REF-Wikipedia-2006" TYPE="REFERENCE">Wikipedia 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-07-08 16:18:22 +0100" MODIFIED_BY="[Empty name]">
<P>Fluphenazine is still one of the drugs commonly used for people with schizophrenia and is given by mouth or short-acting injection. Although we have not found precise data on how much fluphenazine is used worldwide, it is one of the World Health Organization's Essential Drugs (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>) and in the developing world, where non-proprietary preparations of fluphenazine are inexpensive, it may be one of the only drug treatments available. However, although it is still available in most of Europe and North America, the arrival of a newer generation of antipsychotic drugs has reduced its market share in the respective countries. This version of the review updates our past work (<LINK REF="REF-Matar-2007a" TYPE="REFERENCE">Matar 2007a</LINK>; <LINK REF="REF-Matar-2007b" TYPE="REFERENCE">Matar 2007b</LINK>). This is an update of a Cochrane Review first published in 2007 (Issue 1) of <I>The Cochrane Database of Systematic Reviews</I>.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-06-13 11:41:28 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-07-09 14:16:12 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-07-09 14:05:34 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. We included trials described as 'double-blind' if it was implied that the study was randomised and we included these in a sensitivity analysis. If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented these within a subcategory. We excluded quasi-randomised studies, such as those allocating by alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people diagnosed with schizophrenia or schizophrenia-like illnesses using any criteria, irrespective of age, sex or severity of illness.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-05-22 13:13:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Fluphenazine: any dose of only oral administration</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Placebo: (active or inactive) or no treatment</HEADING>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-07-09 14:05:34 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible, outcomes were made binary by dividing them into two categories - 'clinically significant change' and 'no clinically significant change'.<BR/>We categorised outcomes as short term (0-8 weeks), medium term (9 to 26 weeks) and long term (27 weeks to 104 weeks).<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-07-01 14:18:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.1 Not improved or worsened</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.1 General</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2 Specific</HEADING>
<P>2.2.1 Extrapyramidal symptoms (parkinsonian symptoms, dystonia, akathisia, and tardive dyskinesia)</P>
<P>2.2.2 Anticholinergic symptoms</P>
<P>2.2.3 Others</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-07-09 14:05:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.1 Relapse</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.2 Time in exacerbated state</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.3 Leaving the study early</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.4 Length of stay in hospital</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.5 Satisfaction with treatment - participant/carer</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.6 Death</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.1 General symptoms</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2 Specific symptoms</HEADING>
<P>2.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)</P>
<P>2.2.2 Negative symptoms (avolition, poor self-care, blunted affect)</P>
<P>2.2.3 Mood - depression</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Behaviour</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.1 General behaviour</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2 Specific behaviours (e.g. aggressive or violent behaviour)</HEADING>
<P>3.2.1 Social functioning</P>
<P>3.2.2 Employment status during trial (employed/unemployed)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2.3 Occurrence of violent incidents (to self, others or property)</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Economic</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">4.1 Cost of care</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. 'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used the GRADE profiler to import data from Review Manager (RevMan) to create 'Summary of findings' table/s. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P>
<OL>
<LI>Global state - not improved or worsened - medium term.</LI>
<LI>Relapse - long term.</LI>
<LI>Adverse effects: death - long term.</LI>
<LI>Adverse effects: extrapyramidal effects (akathisia) - short term.</LI>
<LI>Adverse effects: extrapyramidal effects (rigidity) - short term.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-06-18 14:46:35 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-06-18 14:46:35 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Cochrane Schizophrenia Group's trials register (May 2012)</HEADING>
<P>The Trial Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register 15th May 2012 using the same search criteria as our initial 2006 review.</P>
<P>For details of previous search please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>[((fluphen* or flufen* or modec* or moditen* or eutimax* or prolixin* or siqualon* or anaten* or dapotum* or decazate* or decafen* or decentan* or fludecate* or lyogen* or lyoridin* or mirenil*) in title, abstract and index fields in REFERENCE) OR (fluphenazin* in interventions field in STUDY)]</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">group module</A>).<BR/>
</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-05-22 13:06:05 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected references of all identified studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each included study for information regarding unpublished trials.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-09 14:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this update are below; for previous methods please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2013-07-08 16:17:46 +0100" MODIFIED_BY="[Empty name]">
<P>For this 2012 update, review authors HEM and MQA inspected citations from the new electronic search and identified relevant abstracts. HEM and MQA also inspected full articles of the abstracts meeting inclusion criteria and carried out the reliability check of all citations from the new electronic search.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-07-09 14:07:47 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>For this update, HEM and MQA extracted data from included studies. We extracted data presented only in graphs and figures whenever possible. When further information was necessary, we contacted authors of studies in order to obtain missing data or for clarification. We encountered multi-centre trials, however, we were unable to extract data relevant to each component centre separately; this was because the study was published many years ago, and such data were unavailable (<LINK REF="STD-Goldberg-1964" TYPE="STUDY">Goldberg 1964</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>
<BR/>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument has not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally, the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. Had enough studies reported continuous data, we would have combined endpoint and change data in the analysis and used mean differences (MD) rather than standardised mean differences (SMD) throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion:</P>
<P>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors;</P>
<P>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>));</P>
<P>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-S min), where S is the mean score and S min is the minimum score.</P>
<P>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants as 'other data' within the <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> rather than into a statistical analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we would have entered such endpoint data into syntheses had we encountered such data.</P>
<P>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not; therefore, we entered skewed change data into analyses regardless of size of study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>Had we encountered such measures, in order to facilitate comparison between trials, we would have converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Had such data been available, we would have made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>); this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we would have used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>We entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for oral fluphenazine. Where keeping to this made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not improved'), we reported data where the left of the line indicates an unfavourable outcome. This was the case with outcome 1.10 Leaving the study early: 3. marked improvement/ hospital discharge (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), which reflected a positive outcome.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-07-09 14:07:59 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, HEM and MQA worked independently by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain additional information. We have noted the level of risk of bias in both the text of the review and in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). For statistically significant results, we used 'Summary of findings' tables to calculate the number needed to treat to provide benefit (NNTB)/to induce harm (NNTH) statistic and its 95% CI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes, we estimated mean difference (MD) between groups.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-07-09 14:09:40 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Had we encountered such studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intra-class correlation coefficients (ICCs) or their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). No cluster trials were identified in this review; however, if in future updates of this review cluster-randomised studies are identified, where the ICC is not reported it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies. This was the case in <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Had we found studies that involved more than two relevant treatment arms, we would have presented the additional treatment arms in comparisons. However, we found no such studies; if, in future updates of this review, if such studies are identified, binary data will be simply added and combined within the two-by-two table. If data are continuous, we will combine data following the formula in section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook for Systemic reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). We chose that, for any particular outcome, should more than 60% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 60% of those in one arm of a study were lost, but the total loss was less than 40%, we would have marked such data with (*) to indicate that such a result may well be prone to bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>In the case where attrition for a binary outcome is between 0% and 60% and where these data are not clearly described, had we found such studies, we would have presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early would be assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, the rate of those who stay in the study - in that particular arm of the trial - would be used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention-to-treat analysis using the above assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>In the case where attrition for a continuous outcome is between 0 and 60%, and data only from people who complete the study to that point are reported, we presented and used these data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>Had standard deviations not been reported, we first would have tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or T value available for differences in mean, we would have calculated them according to the rules described in the <I>Cochrane Handbook for Systemic reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Had only the standard error (SE) been reported, standard deviations (SDs) can be calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systemic reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formula for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formula do not apply, we would have calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. Had we imputed data, and if future updates of this review employ use of imputed data, we will examine the validity of the imputations in a sensitivity analysis excluding the imputed values. Had we needed to, we would have imputed standard deviations using this model for <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-08 16:16:59 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP> test, or a CI for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-07-08 16:16:57 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the C<I>ochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-07-08 16:16:54 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed-effect model for all analyses, but used of the random-effects model where heterogeneity was present.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-08 16:16:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses - only primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Clinical state, stage or problem</HEADING>
<P>We proposed to undertake this review and provide an overview of the effects of oral fluphenazine for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>If inconsistency was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, then we did not pool data and discussed issues. We know of no supporting research for this 10% cut-off, but we used prediction intervals as an alternative to this unsatisfactory state.</P>
<P>When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-07-09 14:16:12 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Hypotheses</HEADING>
<P>It was expected that several sensitivity analyses could be undertaken within this review. The following hypotheses were to be tested:</P>
<P>When compared with placebo, for the primary outcomes of interest (see: <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>), fluphenazine is differentially effective for:</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Men and women.</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 People who are under 18 years of age, between 18 and 64, or over 65 years of age.</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 People who became ill recently (i.e. acute episode approximately less than one month's duration) as opposed to people who have been ill for a longer duration.</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 People who are given low doses (1- 5 mg/day), and those given high doses (over 5 mg/day).</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 People who have schizophrenia diagnosed according to any operational criterion i.e. a pre-stated checklist of symptoms/problems/time periods/exclusions) as opposed to those who have entered the trial with loosely defined illness.</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6 People treated earlier (pre-1990) and people treated in recent years (1990 to 2006).</HEADING>
<P>We additionally applied all sensitivity analyses to the primary outcomes of this review.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we entered all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings of the primary outcomes when we use our assumption/s and when we used data only from people who completed the study to that point. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.</P>
<P>Where assumptions had to be made regarding missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis was undertaken to test how prone results are to change when completer-only data only are compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Risk of bias</HEADING>
<P>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Imputed values</HEADING>
<P>We also sought to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster-randomised trials.</P>
<P>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Fixed-effect and random-effects</HEADING>
<P>We synthesised data using a fixed-effect model; however, we also synthesised data for the primary outcome using a random-effects model to evaluate whether this altered the significance of the results.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-07-09 14:17:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-07-09 14:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies please see the <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK> and <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2013-07-08 17:20:39 +0100" MODIFIED_BY="[Empty name]">
<P>The initial 2006 search yielded 1274 electronic records for 422 studies, of which we rejected 834 during the first inspection. We inspected the remaining 433 papers. Three hundred and forty-three were rejected, as they were clearly not relevant. The remaining 82 papers (55 studies) were considered to match the inclusion criteria closely enough to be mentioned in either the 'Included studies'; 'excluded studies' and 'awaiting classification' tables.</P>
<P>The 2012 update search yielded seven studies, each of which was excluded. The seven studies previously awaiting 'classification' were moved to 'excluded studies' for this review. Therefore, the current review cites 48 studies as 'excluded studies' and 16 reports of the seven 'included studies'. There was over 90% agreement for trial selection and once we had investigated any disagreement and acquired and reassessed the papers, concordance was 100%. Initially, there was also over 90% agreement in the extracted data. We easily resolved any disagreement by discussion (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-07-09 14:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>We included seven studies (total n = 439 participants).</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Methods</HEADING>
<P>In all included studies, randomisation was either reported or implied. The mean duration of treatment was about 170 days (~six months), but this was highly skewed (standard deviation (SD) 253). The most common study length was six weeks (<LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>; <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>; <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK>) but the range was considerable with the longest lasting two years (<LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Setting</HEADING>
<P>Four studies were hospital-based (<LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>; <LINK REF="STD-Goldberg-1964" TYPE="STUDY">Goldberg 1964</LINK>; <LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK>; <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK>), while three were undertaken in the community (<LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>; <LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>). Five studies were conducted in the United States of America (<LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>; <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>; <LINK REF="STD-Goldberg-1964" TYPE="STUDY">Goldberg 1964</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>; <LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>), one in Australia (<LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK>) and one in the United Kingdom (<LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Participants</HEADING>
<P>All trials included participants diagnosed with schizophrenia and two of the seven trials described the diagnostic criteria used (Diagnostic and Statistical Manual version III (DSM-III) or Research Diagnostic Criteria (RDC)). The other studies used a clinical diagnosis of schizophrenia. The mean age of the participants was about 38 years, range 16 to 75, and they were mostly chronic patients with a mean hospitalisation period of about 20 years. In <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>, all participants were men, whilst in <LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK> and <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK> the participants were all women. In the remaining studies participants were of mixed sex.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Study size</HEADING>
<P>The mean number of participants was about n = 60, ranging from 36 to 190.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Interventions</HEADING>
<P>All trials compared oral fluphenazine with inactive placebo. The doses of oral fluphenazine in these studies ranged from 2.5 mg/day (<LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK>) up to a potential of 20 mg/day (<LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>). The mean dose was 8.2 mg per day (SD 3.9). The standard oral dosage in minor disturbances 2 mg to 5 mg/day, or in the treatment of psychotic disorders up to 20 mg to 40 mg daily (<LINK REF="REF-www.psychotropics.dk" TYPE="REFERENCE">www.psychotropics.dk</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.6.1 General remarks</HEADING>
<P>Most outcomes were dichotomous, and presented as such, or were continuous data. In many studies, outcomes were few and where data were reported they were rendered unusable. None of the included studies attempted to quantify levels of satisfaction or quality of life and there is no evidence of any direct economic evaluation of fluphenazine. However, we were able to measure some aspects of the global and mental state and adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Outcome scales</HEADING>
<P>The following scales were used and provided data for the analysis.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.7.1 Global state:</HEADING>
<P>
<I>1.7.1.1 Clinical Global Impression (CGI) </I>
<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>
<BR/>A rating instrument commonly used in studies in schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. <LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK> and <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK> reported dichotomised data from this scale, measuring improvement scores. Continuous data from <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK> were also used in our results, however SDs were imputed using the method described in <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>.</P>
<P>
<I>1.7.1.2 The Multidimensional Scale for Rating Psychiatric Patients (MDRSP)</I> <LINK REF="REF-Lorr-1953" TYPE="REFERENCE">Lorr 1953</LINK>
</P>
<P>The Multidimensional Rating Scale or Hamilton's schizophrenia scale is a modification of the Inpatient Multidimensional Psychiatric Scale. The MDRSP is completed after a psychiatric interview. It consists of 18 items, in the form of simple questions, to be rated along a four-point scale. The severity scores are defined by short behavioural descriptions on the form, thus avoiding interpretation problems. The scale is mainly designed for the evaluation of chronically hospitalised schizophrenic patients. <LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK> reported dichotomised data from this scale for levels of improvement.</P>
<P>
<I>1.7.1.3 Brief Psychiatric Rating Scale (BPRS)</I> <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>
</P>
<P>The scale measures positive symptoms and quantifies factors such as thought disorder, activation, hostility. somatic, hallucinatory, and depressive states. The original scale had 16 items, but a revised 18-item scale is more commonly used, with scores ranging from 0 to 126. Each item is defined on a seven-point scale from 0 = not present to seven = extremely severe. Higher scores equate to severity of illness.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-07-08 16:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 48 studies. Seven were not randomised, did not imply randomisation or did not describe the allocation procedure at all. In one study, participants were not suffering from schizophrenia. Another sizeable proportion of the trials did not compare oral fluphenazine with placebo, but with other treatments. A few were fluphenazine-withdrawal studies which are not relevant to this review. These withdrawal studies will be included in a future review. Three studies had no usable outcomes. Either data did not have clear clinical implications or genuinely relevant clinical data were not adequately reported. Frequently the numbers of participants in each group were not specified, means or SDs were not given or data were not reported from individual arms of cross-over studies. The seven studies identified in the 2012 search were all excluded, owing either to no randomisation (<LINK REF="STD-Kinross_x002d_Wright-1963" TYPE="STUDY">Kinross-Wright 1963</LINK>; <LINK REF="STD-Matheu-1961" TYPE="STUDY">Matheu 1961</LINK>), no diagnosis of schizophrenia (<LINK REF="STD-Hanlon-1970" TYPE="STUDY">Hanlon 1970</LINK>; <LINK REF="STD-Howell-1961" TYPE="STUDY">Howell 1961</LINK>), not the appropriate intervention (<LINK REF="STD-Marder-1993" TYPE="STUDY">Marder 1993</LINK>; <LINK REF="STD-Shafti-2009" TYPE="STUDY">Shafti 2009</LINK>) or no usable data were presented (<LINK REF="STD-Zahn-1993" TYPE="STUDY">Zahn 1993</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Awaiting assessment</HEADING>
<P>No studies are awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We are not aware of any ongoing studies.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-07-08 16:16:01 +0100" MODIFIED_BY="[Empty name]">
<P>Please see the relevant 'Risk of bias' tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2013-03-11 16:34:02 +0000" MODIFIED_BY="[Empty name]">
<P>None of the seven included studies described the methods used to generate random allocation, yet six of them were reported to be "randomly assigned" and readers are given little assurance that bias was minimised during the allocation procedure. <LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK>, did not mention "random assignment", and reported that assignment of participants to fluphenazine or placebo groups was matched on age, length of illness, and severity of illness and the number of participants in each group was identical. <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK> also obtained the same numbers in each group in a randomly assigned procedure with no further description.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-11 16:33:56 +0000" MODIFIED_BY="[Empty name]">
<P>Only two studies (25%) gave a description of their attempts to make the investigation double-blind. <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK> reported that identically appearing medication was administrated from a bottle labelled only with the participant's name and <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK> reported that only the hospital pharmacist knew the composition of the groups. However neither of them actually tested how successful these attempts were. In the other six trials, it was indicated that attempts at blinding had been made, but without any further description.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-03-11 16:34:11 +0000" MODIFIED_BY="[Empty name]">
<P>Five studies reported that participants left the study early. Only two, <LINK REF="STD-Goldberg-1964" TYPE="STUDY">Goldberg 1964</LINK> and <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>, reported specifically the reasons for withdrawal.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-07-08 16:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>Studies frequently presented both dichotomous and continuous data in graphs, or just reported statistical measures of probability (P values). This often made it impossible to acquire raw data for synthesis. Continuous data were frequently poorly described; often no standard deviations/standard errors were presented or no data were presented at all. In this way a lot of potentially informative data were lost. In some studies it seemed that attempts had been made to use the original trials as vehicles for answering a host of other questions about schizophrenia. As a consequence, data from the randomised parts of the studies became buried beneath copious subgroup analyses.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-07-08 16:15:52 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of trials has been assessed in individual 'Risk of bias' tables under the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section, using the guidance from the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> categories (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Due to poor reporting standards from particularly old studies, the majority of the risk of bias domains have been rated 'unclear' for the risk of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. COMPARISON: ORAL FLUPHENAZINE versus PLACEBO</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 Not improved or worsened</HEADING>
<P>We found no significant difference between oral fluphenazine and placebo for 'not improved or worse' (CGI) over short-term assessment (n = 125, 3 RCTs). Dichotomised multidimensional rating scale scores at 12 weeks 'not improved or worse' were also non-significant (n = 50, 1 RCT, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 Relapse</HEADING>
<P>Only <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK> reported on relapse up to six weeks (short term) with results indicating a trend favouring fluphenazine (n = 38, 1 RCT, risk ratio (RR) 0.25 95% confidence interval (CI) 0.06 to 1.03, P = 0.05). Two studies, <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK> and <LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>, reported data for long-term relapse, which significantly favoured fluphenazine but data are heterogeneous (I<SUP>2</SUP> 92%). Using a random-effects model rendered data equivocal (n = 86, 2 RCTs, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.3 Percentage of time in prodrome state</HEADING>
<P>
<LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK> reported data at one- and two-year time points, but data are skewed (high SDs) and are best inspected outside of a forest plot, using an additional table (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The data suggest that a greater amount of time was spent in a prodromal state amongst placebo participants, at both one and two years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.4 Percentage of time in exacerbated state</HEADING>
<P>Again, <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK> reported data at one- and two-year time points, but data are skewed and are best inspected outside of a forest plot, using an additional table (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Data suggest that, by one year, participants receiving oral fluphenazine spent more time in an exacerbated state that those on placebo. However, by two years, people receiving placebo spent longer in an exacerbated state.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.5 CGI severity of illness - average score</HEADING>
<P>Data for global state using the CGI were reported in one study (<LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>), which demonstrated greater improvement in global state (n = 36, 1 RCT, mean difference (MD) -0.77 95% CI -1.39 to -0.15), this was a statistically significant result (P = 0.02); however, these data were imputed using the adjusted final mean and the P value between studies, and the significance of the results should be treated with caution (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving study early</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Non-specific reasons</HEADING>
<P>Although people allocated to oral fluphenazine left the study less often than participants who were given placebo in the short term, the data did not reach statistical significance (n = 227, 2 RCTs). For -medium-term assessment, we found only one study reporting on attrition (n = 50) and data were not significantly different. Long-term follow-up from two studies (n = 86) were also equivocal, and as a proxy measure for treatment acceptability the oral fluphenazine group did not find treatment any more acceptable than the placebo group when assessed over short-, medium- and long-term evaluation. Overall, across all time periods, only about 15% of people left these studies early (n = 363, 5 RCTs, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Specific reasons</HEADING>
<P>Leaving the study early due to court case transfers was significantly higher (P = 0.02) in the fluphenazine group (n = 190, 1 RCT, RR 10.65 95% CI 1.39 to 81.58). Other reasons for leaving the study early: 'incorrect diagnosis' (n = 190, 1 RCT), 'marked early remission' (n = 190, 1 RCT) and 'serious complication of treatment' (n = 190, 1 RCT) were not significantly different. We found the number of participants leaving the study early due to treatment failure favoured oral fluphenazine with significantly more people dropping out from the placebo group (n = 190, 1 RCT, RR 0.11 95% CI 0.03 to 0.35, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Marked improvement/ hospital discharge</HEADING>
<P>Data were equivocal for this positive outcome (forest plots are presented to display results right to the line of no effect, indicating a favourable outcome for oral fluphenazine). Only one participant receiving oral fluphenazine in one small study was discharged due to marked improvement (n = 36, 1 RCT, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 Anticholinergic effects</HEADING>
<P>There is some suggestion that fluphenazine increases a person's chance of experiencing anticholinergic effects such as constipation (n = 190, 1 RCT, RR 2.22 95% CI 1.19 to 4.15), dry mouth (n = 227, 2 RCTs, RR 3.62 95% CI 1.39 to 9.42) and increased salivation (n = 190, 1 RCT, RR 18.10 95% CI 1.06 to 309.15). Data for blurred vision, drooling, gastrointestinal distress, nasal congestion, urinary disturbance, and vomiting were not significantly different (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 Cardiovascular effects</HEADING>
<P>No significant differences were found between fluphenazine and placebo for dizziness/faintness/weakness (n = 190, 1 RCT), hypotension (n = 37, 1 RCT), syncope (n = 37, 1 RCT), or tachycardia (n = 37, 1 RCT, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.3 Central nervous system</HEADING>
<P>There is also some suggestion that fluphenazine increases a person's chance of experiencing some neurological symptoms such as drowsiness (n = 190, 1 RCT, RR 3.91 95% CI 1.98 to 7.71). Reports of headache did not reveal any significant differences between fluphenazine and placebo groups (n = 190, 1 RCT). Other outcomes, anxiety, convulsion/seizures, depression, sedation/lethargy were equivocal (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.4 Death</HEADING>
<P>Only one study (<LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>) reported on the outcome of death, with one death occurring in the fluphenazine group during long-term follow-up (n = 50, 1 RCT, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.5 Endocrine</HEADING>
<P>We found no statistically significant difference between fluphenazine and placebo for the outcomes of amenorrhoea (n = 190, 1 RCT), lactation (n = 190, 1 RCT) or swelling of the breasts (n = 190, 1 RCT) at short term (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.6 Extrapyramidal effects</HEADING>
<P>In the short term, there is evidence that fluphenazine increases a person's chances of experiencing akathisia (n = 227, 2 RCTs, RR 3.43 95% CI 1.23 to 9.56), facial rigidity (n = 190, 1 RCT, RR 2.77 95% CI 1.03 to 7.46), 'loss of associated movements' (n = 190, 1 RCT, RR 6.39 95% CI 1.95 to 20.98), rigidity (n = 227, 2 RCTs, RR 3.54 95% CI 1.76 to 7.14) and tremor (n = 227, 2 RCTs, RR 3.19 95% CI 1.25 to 8.11). We found measures of akinesia, associated movements, dystonia and restlessness/insomnia were not significantly different from those allocated to placebo. Evidence in the medium term indicates that fluphenazine increases the likelihood of having parkinsonism (n = 50, 1 RCT, RR 5.50 95% CI 1.36 to 22.32), but akathisia, akinesia and dystonia were equivocal (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.7 Other</HEADING>
<P>We did not find any statistically significant data for the outcomes of convulsion/seizures (n = 190, 1 RCT), diarrhoea (n = 190, 1 RCT), infection (n = 190, 1 RCT), or rash (n = 227, 2 RCTs, <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. SENSITIVITY ANALYSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Men and women</HEADING>
<P>Three studies included either all male (<LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>) or all female (<LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK>; <LINK REF="STD-Millar-1963" TYPE="STUDY">Millar 1963</LINK>) participants. However, only <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK> reported data for any of our primary outcomes; therefore, a sensitivity analysis was not possible for this comparison. Note HM: this section is repeated below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 People who are under 18 years of age, between 18 and 64, or over 65 years of age</HEADING>
<P>The age ranges of all participants across the included studies were all similar (between 16 and 58 years old). Where participants younger than 18 were included in the relevant studies (the youngest being 16 years old in <LINK REF="STD-Goldberg-1964" TYPE="STUDY">Goldberg 1964</LINK>, and 17 years old in <LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>), it was not possible to extract their data from the individual reports. Therefore, a sensitivity analysis has not been undertaken.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Chronic versus acutely ill people (&lt; one month in duration)</HEADING>
<P>Limited data were available from only one study. Participants who were chronically ill did not leave the study early in greater numbers than acutely ill patients. We found relapse did occur more often in the placebo arm of those chronically ill compared with those acutely ill, but the sample sizes were small and uneven and more data are required to draw any inferences (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Low doses (1-5 mg/day) and high doses (over 5 mg/day)</HEADING>
<P>Again, limited data were available, but it is suggested that there is little difference between levels of improvement between participants in studies that used either a high dose (15 mg/day used in <LINK REF="STD-Carpenter-1999" TYPE="STUDY">Carpenter 1999</LINK>; n = 38, 1 RCT) or a flexible dose regimen in the short term (2-10 mg/day in <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>; or up to 14 mg/day in <LINK REF="STD-Hordern-1964" TYPE="STUDY">Hordern 1964</LINK>; n = 87, 2 RCTs, <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Diagnosed according to any operational criterion versus those with loosely defined illness</HEADING>
<P>It is indicated that there is again little difference in results for no improvement when participants have been diagnosed according to operational criteria (DSM-III-R, n = 38, 1 RCT) or with loose diagnostic criteria or definitions (n = 87, 2 RCTs, <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Studies published before 1990 versus studies published between 1990 and the present</HEADING>
<P>Data were available for the outcomes of 'no global improvement' in the short term. There were no clear differences between the results of earlier studies and those published in the last 16 years (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Implication of randomisation</HEADING>
<P>Only one study was rated as a low risk of bias for adequate randomisation (<LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK>); results for the primary outcome of global state (not improved or worse) remain the same when all other studies that implied randomisation were removed from the meta-analysis (n = 37, 1 RCT, RR 0.59, 95% CI 0.24 to 1.42). For the other secondary outcomes of adverse effects; the effect of removing the other studies that were meta-analysed with <LINK REF="STD-Clark-1971" TYPE="STUDY">Clark 1971</LINK> and implied as being randomised is that data are no longer statistically significant for short-term extrapyramidal akathisia (from P = 0.02 to P = 0.18), or tremor (P = 0.01 to P = 0.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Assumptions for lost binary data</HEADING>
<P>There were no clear differences between the results when completer-only data were used compared to data assumed for those lost to follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Risk of bias</HEADING>
<P>Each included study was rated as a 'high' risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. The result of excluding each study on this basis leaves us with no data to compare, therefore a sensitivity analysis was not possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.10 Imputed values</HEADING>
<P>We also sought to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster-randomised trials. However, we encountered no such studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.11 Fixed-effect and random-effects</HEADING>
<P>We found that there was no difference in the results when synthesising data for the primary outcome of global state (not improved or worse) using a random-effects model. However, for short-term extrapyramidal effects (tremor), when using a random-effects model, results were no longer statistically significant (from P = 0.01 to P = 0.07).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-07-09 14:27:55 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-07-09 14:27:01 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. COMPARISON ONE: ORAL FLUPHENAZINE versus PLACEBO</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Global State</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 No improvement</HEADING>
<P>There were few data available for global improvement. Data were only obtained from three studies, and both short-term and medium-term assessment did not reveal any significant differences between fluphenazine and placebo, although a trend may be evident from the graphical representations of the data, suggesting that oral fluphenazine is superior to placebo, and perhaps this would have clearly emerged if larger and longer studies were used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 Relapse</HEADING>
<P>There are surprisingly little data regarding relapse but the strongest results come from a small study with a duration of one year (<LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>), however, there was substantial heterogeneity present, perhaps due to the difference between the participant population and stages (remitted, non-psychotic participants in <LINK REF="STD-Rifkin-1976" TYPE="STUDY">Rifkin 1976</LINK>, and participants with at least two episodes of acute schizophrenia or continuing psychotic symptoms in previous two years in <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>). A larger sample size would have probably ensured more unequivocal data in favour of fluphenazine.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving study early</HEADING>
<P>The finding that using fluphenazine resulted in more people staying in the study could be seen as heartening. Perhaps a genuine decrease in the distressing symptoms of schizophrenia leads to an increased concordance with medication, despite the unpleasant adverse effects of this drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<P>In spite of more than five decades of research on this benchmark antipsychotic treatment, very little can be said from trials regarding its direct effect on mental state regarding general or specific symptoms of schizophrenia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Adverse effects</HEADING>
<P>Although we were able to include a few studies in this review, clinicians will not be surprised that fluphenazine produces acute extrapyramidal disorders; dystonia, parkinsonism, akathisia, tremor, rigidity, weakness and anticholinergic effects. This Cochrane review, however, is a rare report of the best available and quantitative data on a compound over half a century old. Estimates of the incidence of extrapyramidal disorders, however, are not available from this review, as these necessitate a long follow-up period that was only attempted in a few trials. It may be surprising that there was only one death incident reported among over 439 people with schizophrenia who were randomised to oral fluphenazine or placebo. The lifetime incidence of suicide for people suffering from schizophrenia is 10% to 13% (<LINK REF="REF-Caldwell-1992" TYPE="REFERENCE">Caldwell 1992</LINK>). The occurrence of only one death indicates that either trial-care is more vigilant than routine care or that death is an under-reported outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. SENSITIVITY ANALYSES</HEADING>
<P>As we knew would be likely from the start, the power to detect a real difference between studies in any one of the sensitivity analyses was very low. Only subsets of already limited lists of trials were available. The wide confidence intervals could be hiding true differences in effect between the acutely and chronically ill people, and early trials versus current studies.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-07-09 14:27:25 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Generalisability</HEADING>
<P>This work includes studies that span nearly four decades of evaluative studies within psychiatry. It is possible that the rigour of these experiments has changed over time, as have the participants. There is some empirical evidence that the quality of schizophrenia trial reporting has not changed much over time (<LINK REF="REF-Thornley-1998" TYPE="REFERENCE">Thornley 1998</LINK>) or, if it has changed, it may even have deteriorated (<LINK REF="REF-Ahmed-1998" TYPE="REFERENCE">Ahmed 1998</LINK>). We have found no time-related differences in reporting of studies within this review and no suggestion of a change of the effect size over time. We identified trials by meticulous searching; nevertheless, for a compound formulated so long ago, publication biases may be difficult to avoid. The strength of this review is that it presents up-to-date quantitative data for a benchmark treatment for schizophrenia which is used throughout the world.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Applicability</HEADING>
<P>The seven included studies involve many people who would be recognisable in everyday practice. There are those with strictly diagnosed illnesses, very likely to suffer from schizophrenia, and people whose illness was diagnosed using less rigorous criteria. The dose of fluphenazine in the studies included in this review could be considered standard (mean 8.2 mg/day SD 3.9). Although the outcomes that have been used in this review are accessible to both clinicians and recipients of care, generalising to treatment in community settings, could be problematic. Four studies were undertaken in hospital and three in the community, which is where most people with schizophrenia now reside.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Heterogeneity</HEADING>
<P>Two outcomes were heterogeneous, but all other outcomes were homogeneous. However, no more than five studies were pooled so the chances of data being heterogeneous were always small. In addition, several methods were used to observe different adverse effects e.g. tremor and blurred vision. This made analyses and interpretation for the results even more difficult.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Limited data</HEADING>
<P>Data were often inadequately reported and rendered many outcomes unusable. Most trials report only six- to 12-week outcomes for a mostly lifelong illness. No studies reported on service utilisation, economic outcomes, or on satisfaction with care.<BR/>
</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-07-09 14:27:55 +0100" MODIFIED_BY="[Empty name]">
<P>Generally, the quality of the available evidence was rated as either <I>very low, low </I>to <I>moderate </I>(See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). This was largely due to the age of the included studies and poor reporting standards, some of which were published up to 50 years ago, pre-dating the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>; <LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>). Missing or unreported outcomes were common, which restricted the amount of evidence available for use in this systematic review and data that may have been relevant in meta-analysis. Any future studies in this area must adhere to CONSORT principles, ensuring that all trials are transparently reported, that all tables and figures express what data they are presenting, so that no trials can reach publication without revelation of methodological inadequacies. A flow diagram should also be used in order to document the process in which participants are recruited to those that are ultimately followed-up, promoting completeness, clarity and transparency of reporting.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-03-18 14:38:23 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors sought to adhere to the protocol, through the independent inspection of citations and full articles of potentially relevant studies. Furthermore, the review authors independently extracted data onto standard simple forms; however, we met for discussion where inconsistencies or disagreements arose regarding the available data. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-03-18 15:26:50 +0000" MODIFIED_BY="[Empty name]">
<P>We are not aware of other systematic reviews evaluating the effects of oral fluphenazine versus placebo in the treatment of schizophrenia. </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-07-09 14:28:48 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-07-09 14:28:39 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For people with schizophrenia</HEADING>
<P>Many people with schizophrenia and their non-professional carers recognise psychotic symptoms as phenomena generated by a damaging and pernicious illness and may see the effect of fluphenazine, as demonstrated within this review, as positive. Others may consider these data as supporting well-publicised objections to the use of drugs; drugs potent in their ability to cause unpleasant adverse effects, and to potentially erode a person's ability to make informed decisions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>This review will confirm much that clinicians already know, but it does provide some quantification to support clinical impression. Fluphenazine is an antipsychotic, prone to cause a variety of extrapyramidal and anticholinergic effects. Evidence about its short-term antipsychotic effect is weak. However, fluphenazine is a low-cost and widely available choice for the clinician. Despite its many adverse effects, fluphenazine is likely to remain one of the most widely used treatments for schizophrenia worldwide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers or policy makers</HEADING>
<P>Fluphenazine is widely available and inexpensive. It is understandable that it remains one of the many drugs used for treating people with serious mental illnesses. However, some of fluphenazine's adverse effects could be expensive in terms of human suffering and cost of treatment. It could, therefore, be more beneficial to use another drug if the latter was equally potent, but had a more favourable adverse-effect profile.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-07-09 14:28:48 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>So much more could have been learnt about the effects of oral fluphenazine if the studies in this review had clearly described the method of allocation and the integrity of blinding; especially for the more subjective outcomes. Most included studies, however, predated the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). Concrete and simple outcomes are of interest. For example, clearly reporting improvement, 'number of violent incidents', 'relapse' (giving some description of criteria), 'hospital discharge or admission', and 'presence of delusions or hallucinations' would have been helpful, and simple reporting of levels of satisfaction and quality of life would have been very informative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<P>Even though fluphenazine has been used as an antipsychotic drug for decades, there are still a surprisingly small number of well-conducted randomised, placebo-controlled trials measuring its efficacy and potential to cause adverse effects. The use of oral fluphenazine for millions of people is based on clinical experience rather than the poorly reported trials that involve, in total, only a few hundred participants. Clinicians and researchers are mainly satisfied with the current levels of understanding, and, therefore new studies evaluating oral fluphenazine versus placebo will be very rare. The fluphenazine story is, however, incomplete. Questions remain regarding the effect of this drug on mental state and long-term extrapyramidal effects. One or more large, methodologically sound, randomised, placebo-controlled trials could help answer these questions. With the advent of universally available effective, even moderately effective, antipsychotic drugs, the day for studies comparing oral fluphenazine with placebo has passed.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-03-18 14:20:50 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank members of the Cochrane Schizophrenia Group, Prof. Clive E Adams, Tessa Grant and Judy Wright for their continuing support. Thanks also go to Dr. Adib Essali who first introduced us to The Cochrane Collaboration.</P>
<P>The Cochrane Schizophrenia Group produce and maintain a template for the methods section of their reviews. We have used this template and adapted it for our requirements.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-09 14:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>Hosam E Matar screened the search results, organised the retrieval of papers, appraised the papers and extracted data, analysed and interpreted the data, managed the data and entered data in RevMan, and wrote the final report.</P>
<P>Muhammad Qutayba Almerie screened the search results, organised the retrieval of papers, appraised the papers and extracted data, managed the data and entered data in RevMan, analysed and interpreted the data and wrote the final report.</P>
<P>Stephanie Sampson updated the abstract, search and results section, constructed PRISMA diagram and Summary of findings table.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-07-09 13:45:01 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-07-09 13:45:01 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-07-09 13:45:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1999" MODIFIED="2013-07-08 16:06:58 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-08 16:06:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Breier AF</AU>
<TI>Diazepam treatment of early signs of exacerbation in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>2</NO>
<PG>299-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99178642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1971" NAME="Clark 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP</AU>
<TI>Drug treatment in newly admitted schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1971</YR>
<VL>25</VL>
<NO>5</NO>
<PG>404-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72081786"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1964" MODIFIED="2013-07-09 13:45:01 +0100" MODIFIED_BY="Heather Maxwell" NAME="Goldberg 1964" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:54:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cole JO, Goldberg SC, Klerman GL</AU>
<TI>Phenothiazine treatment in acute schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1964</YR>
<VL>10</VL>
<PG>246-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71204770"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibbons RD, Lewine RRJ, Davis JM, Schooler NR, Cole JO</AU>
<TI>An empirical test of a kraepelinian vs. a bleulerian view of negative symptoms</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1985</YR>
<VL>11</VL>
<NO>3</NO>
<PG>390-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71204770"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-09 13:45:01 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Klerman GL, Cole JO</AU>
<TI>Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1965</YR>
<VL>111</VL>
<PG>120-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5677325"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Mattsson N, Cole JO, Klerman GL</AU>
<TI>Prediction of improvement in schizophrenia under four phenothiazines</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1967</YR>
<VL>16</VL>
<PG>107-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6066689"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Mattsson NB</AU>
<TI>Schizophrenic subtypes defined by response to drugs and placebo</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1968</YR>
<VL>29</VL>
<NO>5</NO>
<PG>S153-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68399894"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klerman GL, Goldberg SG, Davis D</AU>
<TI>Relationship between the hospital milieu and the response to phenothiazines in the treatment of schizophrenics</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1970</YR>
<VL>70</VL>
<NO>6</NO>
<PG>716-29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71204770"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hordern-1964" MODIFIED="2013-07-01 11:54:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hordern 1964" YEAR="">
<REFERENCE MODIFIED="2013-07-01 11:54:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hordern A, King A, Holt NF, Collins J, Toussaint J</AU>
<TI>Thioproperazine in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>110</VL>
<PG>531-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79181666"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marder-1994" MODIFIED="2013-07-08 16:07:25 +0100" MODIFIED_BY="Heather Maxwell" NAME="Marder 1994" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:07:25 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Wirshing WC, van Putten T, Mintz J, McKenzie J, Johnston-Cronk K, et al</AU>
<TI>Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>4</NO>
<PG>280-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94213575"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millar-1963" NAME="Millar 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millar J</AU>
<TI>A trial of fluphenazine in schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1963</YR>
<VL>109</VL>
<PG>428-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="769023"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rifkin-1976" MODIFIED="2013-07-01 11:56:53 +0100" MODIFIED_BY="[Empty name]" NAME="Rifkin 1976" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Quitkin F, Kane J, Klein DF, Ross D</AU>
<TI>The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics</TI>
<SO>Biological Psychiatry</SO>
<YR>1979</YR>
<VL>14</VL>
<NO>3</NO>
<PG>499-508</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="224958"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 64-08562"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Quitkin F, Kane J, Klein DF</AU>
<TI>Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>2</NO>
<PG>40-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="323910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Quitkin F, Klein DF</AU>
<TI>Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>10</NO>
<PG>15-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78019044"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 11:56:53 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Quitkin F, Rabiner CJ, Klein DF</AU>
<TI>Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1976</YR>
<VL>12</VL>
<NO>2</NO>
<PG>24-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="769022"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Quitkin F, Rabiner CJ, Klein DF</AU>
<TI>Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77111134"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-07-08 16:09:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1994" MODIFIED="2013-07-08 16:07:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="Adler 1994" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:07:34 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R,</AU>
<TI>Vitamin E treatment for tardive dyskinesia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>9</NO>
<PG>836-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1999313441"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 12:00:24 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler LA, Rotrosen J, Lavori P, Edson R</AU>
<TI>Vitamin E treatment of TD: development of a VA cooperative study</TI>
<SO>Biological Psychiatry</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>730-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11760"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-08 16:07:40 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P, Edson R, et al</AU>
<TI>Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study 394</TI>
<SO>Psychopharmacology</SO>
<YR>1997</YR>
<VL>132</VL>
<NO>1</NO>
<PG>61-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1997216311"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baladini-1970" NAME="Baladini 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldini JT, Neary ER</AU>
<TI>Controlled trials of an amitriptyline-fluphenazine combination in depressive neuroses and psychoses: a collaborative study</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>2</NO>
<PG>84-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70113586"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyer-1995" MODIFIED="2013-07-01 12:01:09 +0100" MODIFIED_BY="Heather Maxwell" NAME="Boyer 1995" YEAR="">
<REFERENCE MODIFIED="2013-07-01 12:01:09 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F</AU>
<TI>Treatment of negative symptoms in schizophrenia with amisulpride</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>166</VL>
<NO>1</NO>
<PG>68-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7894879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Lecrubier Y, Puech AJ</AU>
<TI>Treatment of positive and negative symptoms: pharmacologic approaches</TI>
<SO>Modern Problems of Pharmacopsychiatry</SO>
<YR>1990</YR>
<VL>24</VL>
<PG>152-74</PG>
<ED>Andreasen NC</ED>
<PB>S. Karger</PB>
<CY>Basel,Switzerland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11782241"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Puech AJ, Lecrubier Y</AU>
<TI>Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results</TI>
<TO>Etude en double insu contre placebo de l'amisulpride (Solian (r) 50) a faible dose chez des schizophrenes purement deficitaires. Premiere analyse des resultats</TO>
<SO>Annales de Psychiatrie</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>3</NO>
<PG>321-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1988242981"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Puech AJ</AU>
<TI>Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools</TI>
<TO>Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises</TO>
<SO>Psychiatrie and Psychobiologie</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>4</NO>
<PG>296-305</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 76-12830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lecrubier Y</AU>
<TI>Amisulpride in deficit schizophrenia</TI>
<SO>6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7894879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rein W, Turjanski S</AU>
<TI>Clinical update on amisulpride in deficit schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>Suppl 2</NO>
<PG>S19-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97361270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-1987" MODIFIED="2013-07-08 16:07:47 +0100" MODIFIED_BY="Heather Maxwell" NAME="Breier 1987" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:07:47 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, et al</AU>
<TI>Neuroleptic responsivity of negative and positive symptoms in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<PG>1549-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3688278"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1992" MODIFIED="2013-07-08 16:07:53 +0100" MODIFIED_BY="Heather Maxwell" NAME="Carpenter 1992" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:07:53 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Buchanan RW, Breier A, Kirkpatrick B, Hanlon T, Levine J, et al</AU>
<TI>Novel neuroleptic dosage reduction strategies</TI>
<SO>Schizophrenia Research</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>2</NO>
<PG>107</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3688278"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chacon-1972" MODIFIED="2013-07-01 12:02:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Chacon 1972" YEAR="">
<REFERENCE MODIFIED="2013-07-01 12:02:26 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chacon C, Harper P, Harvey GF</AU>
<TI>Work study in the assessment of the effects of phenothiazines in schizophrenia</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1972</YR>
<VL>13</VL>
<NO>6</NO>
<PG>549-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73051431"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1973-31686-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chacon-1973" NAME="Chacon 1973" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chacon C, Harper P</AU>
<TI>Clinical and work performance variables in phenothiazine therapy of schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1973</YR>
<VL>49</VL>
<NO>1</NO>
<PG>65-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4572169"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coffman-1987" MODIFIED="2013-07-08 16:08:00 +0100" MODIFIED_BY="Heather Maxwell" NAME="Coffman 1987" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:08:00 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coffman JA, Nasrallah HA, Lyskowski J, McCalley-Whitters M, Dunner FJ</AU>
<TI>Clinical effectiveness of oral and parenteral rapid neuroleptization</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>1</NO>
<PG>20-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1987061089"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Giudice-1975" MODIFIED="2013-07-01 12:05:10 +0100" MODIFIED_BY="Heather Maxwell" NAME="Del Giudice 1975" YEAR="">
<REFERENCE MODIFIED="2013-07-01 12:05:10 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Giudice J, Clark WG, Gocka EF</AU>
<TI>Prevention of recidivism of schizophrenics treated with fluphenazine enanthate</TI>
<SO>Psychosomatics</SO>
<YR>1975</YR>
<VL>16</VL>
<NO>1</NO>
<PG>32-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76032528"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 54-12277"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doran-1990" NAME="Doran 1990" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doran AR, Labarca R, Wolkowitz OM, Roy A, Douillet P, Pickar D</AU>
<TI>Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with Schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>558-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2350208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dowing--1963" NAME="Dowing  1963" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Downing RW, Ebert JN, Shubrooks SJ</AU>
<TI>Effect of phenothiazines on the thinking of acute schizophrenics</TI>
<SO>Perceptual and Motor Skills</SO>
<YR>1963</YR>
<VL>17</VL>
<NO>2</NO>
<PG>511-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1964-06498-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elman-1999" MODIFIED="2013-07-08 16:08:16 +0100" MODIFIED_BY="Heather Maxwell" NAME="Elman 1999" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:08:16 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM, et al</AU>
<TI>Mechanism of peripheral noradrenergic stimulation by clozapine</TI>
<SO>Neuropyschopharmacology</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>1</NO>
<PG>29-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99103168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haider-1968" NAME="Haider 1968" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haider I</AU>
<TI>A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>114</VL>
<NO>512</NO>
<PG>837-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4874164"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1970" MODIFIED="2012-07-10 03:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Hanlon 1970" YEAR="1970">
<REFERENCE MODIFIED="2012-07-10 03:37:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Ota KY, Kurland AA</AU>
<TI>Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1970</YR>
<VL>31</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4909632"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Held-1970" NAME="Held 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Held JM, Cromwell RL, Frank ET Jr, Fann WE</AU>
<TI>Effect of phenothiazines on reaction time in schizophrenics</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1970</YR>
<VL>7</VL>
<NO>3</NO>
<PG>209-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70166858"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarty-1979" NAME="Hogarty 1979" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E</AU>
<TI>Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1979</YR>
<VL>36</VL>
<NO>12</NO>
<PG>1283-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80041623"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holden-1970" NAME="Holden 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holden JM, Itil TM, Keskiner A</AU>
<TI>Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy</TI>
<SO>Biological Psychiatry</SO>
<YR>1970</YR>
<VL>2</VL>
<NO>2</NO>
<PG>173-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4918019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howell-1961" MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Howell 1961" YEAR="1961">
<REFERENCE MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howell RJ, Brown HM, Beaghler HE</AU>
<TI>A comparison of fluphenazine, trifluoperazine and a placebo in the context of an active treatment unit</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1961</YR>
<VL>132</VL>
<PG>522-30</PG>
<CY>Not Available</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13716275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itil-1971" NAME="Itil 1971" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itil TM, Saletu B, Hsu W, Kiremitci N, Keskiner A</AU>
<TI>Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1971</YR>
<VL>47</VL>
<NO>4</NO>
<PG>440-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4947806"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itil-1975" NAME="Itil 1975" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itil TM, Marasa J, Saletu B, Davis S, Mucciardi AN</AU>
<TI>Computerized EEG: predictor of outcome in schizophrenia</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1975</YR>
<VL>160</VL>
<NO>3</NO>
<PG>188-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75116033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-1982" NAME="Kane 1982" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos Lorenzi J</AU>
<TI>Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<NO>1</NO>
<PG>70-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82112452"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinross_x002d_Wright-1963" MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Kinross-Wright 1963" YEAR="1963">
<REFERENCE MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinross-Wright J, Vogt AH, Charalampous KD</AU>
<TI>A new method of drug therapy</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1963</YR>
<VL>119</VL>
<PG>779-80</PG>
<CY>Not Available</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14032917"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinross_x002d_Wright-1964" MODIFIED="2013-07-01 12:08:08 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kinross-Wright 1964" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinross-Wright J, Charalampous KD</AU>
<TI>A controlled study of a very long-acting phenothiazine preparation</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1964</YR>
<VL>1</VL>
<PG>66-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 60-03426"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leff-1971" MODIFIED="2013-07-01 12:08:55 +0100" MODIFIED_BY="Heather Maxwell" NAME="Leff 1971" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK</AU>
<TI>Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>1</VL>
<NO>854</NO>
<PG>633-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4571196"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 12:08:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leff JP, Wing JK</AU>
<TI>Trial of maintenance therapy in schizophrenia</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>3</VL>
<NO>775</NO>
<PG>599-604</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71287275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Litman-1994" NAME="Litman 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Litman RE, Hommer DW, Radant A, Clem T, Pickar D</AU>
<TI>Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>2</NO>
<PG>107-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94318574"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marder-1989" MODIFIED="2013-07-08 16:08:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Marder 1989" YEAR="">
<REFERENCE MODIFIED="2013-07-08 16:08:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, et al</AU>
<TI>Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>3</NO>
<PG>479-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2626520"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marder-1993" MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Marder 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Wirshing WC, Eckman T</AU>
<TI>Psychosocial and pharmacological strategies for maintenance therapy: effects on two - year outcome</TI>
<SO>Schizophrenia Research</SO>
<YR>1993</YR>
<VL>9</VL>
<PG>260</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1975" NAME="Martin 1975" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin IC</AU>
<TI>Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1975</YR>
<VL>51</VL>
<NO>2</NO>
<PG>110-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="235189"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matheu-1961" MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Matheu 1961" YEAR="1961">
<REFERENCE MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matheu H, Fogel EJ</AU>
<TI>Clinical effects of fluphenazine dihydrychloride in chronic schizophrenia</TI>
<SO>Journal of Neuropsychiatry</SO>
<YR>1961</YR>
<VL>3</VL>
<PG>105-11</PG>
<CY>Not Available</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14471099"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattes-1984" NAME="Mattes 1984" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattes JA, Nayak D</AU>
<TI>Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives</TI>
<SO>Biological Psychiatry</SO>
<YR>1984</YR>
<VL>19</VL>
<NO>3</NO>
<PG>445-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6722235"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 72-10290"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichot-1988" MODIFIED="2013-07-01 12:10:14 +0100" MODIFIED_BY="Heather Maxwell" NAME="Pichot 1988" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Lecrubier Y, Puech AJ</AU>
<TI>Treatment of positive and negative symptoms: pharmacologic approaches</TI>
<SO>Modern Problems of Pharmacopsychiatry</SO>
<YR>1990</YR>
<VL>24</VL>
<PG>152-74</PG>
<ED>Andreasen NC</ED>
<PB>S. Karger</PB>
<CY>Basel,Switzerland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11782241"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Puech AJ</AU>
<TI>Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools</TI>
<TO>Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises</TO>
<SO>Psychiatrie and Psychobiologie</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>4</NO>
<PG>296-305</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 76-12830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 12:10:14 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pichot P, Boyer P</AU>
<TI>A double blind, controlled, multicenter trial of low dose amisulpride (Solian(R) 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia</TI>
<TO>Essai multicentrique controle, en double insu, amisulpride (solian(r) 50) contre fluphenazine a faibles doses dans le traitement du syndrome deficitaire des schizophrenies chroniques</TO>
<SO>Annales de Psychiatrie</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>3</NO>
<PG>312-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1988242980"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pickar-1986" NAME="Pickar 1986" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM</AU>
<TI>Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1986</YR>
<VL>43</VL>
<NO>7</NO>
<PG>669-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3718170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pickar-1992" MODIFIED="2013-07-01 12:10:46 +0100" MODIFIED_BY="Heather Maxwell" NAME="Pickar 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pickar D, Owen RR, Litman RE, Hsiao JK, Su TP</AU>
<TI>Predictors of clozapine response in schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>Suppl B</NO>
<PG>129-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95050371"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 12:10:46 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH</AU>
<TI>Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>5</NO>
<PG>345-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92264872"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quitkin-1978" NAME="Quitkin 1978" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quitkin F, Rifkin A, Kane J, Ramos Lorenzi JR, Klein DF</AU>
<TI>Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<NO>7</NO>
<PG>889-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78234523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sampath-1992" NAME="Sampath 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sampath G, Shah A, Krska J, Soni SD</AU>
<TI>Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels</TI>
<SO>Human Psychopharmacology</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>4</NO>
<PG>255-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1992364197"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schlosberg-1978" NAME="Schlosberg 1978" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schlosberg A, Shadmi M</AU>
<TI>A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate</TI>
<SO>Current Therapeutic Research</SO>
<YR>1978</YR>
<VL>23</VL>
<NO>5</NO>
<PG>642-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 62-01680"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-1976" MODIFIED="2013-07-08 16:09:35 +0100" MODIFIED_BY="Heather Maxwell" NAME="Schooler 1976" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelenberg AJ, Doller JC, Schooler NR, Mieske M, Severe J, Mandel MR</AU>
<TI>Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>136</VL>
<PG>217-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79101484"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-08 16:09:30 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, et al</AU>
<TI>Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study</TI>
<SO>Advances in Biochemical Psychopharmacology</SO>
<YR>1980</YR>
<VL>24</VL>
<PG>483-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80262441"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M</AU>
<TI>Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<NO>2</NO>
<PG>197-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82159410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 12:12:07 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Levine J, +NIMH-PRB Collaborative Fluphenazine Study Group</AU>
<TI>The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1976</YR>
<VL>9</VL>
<NO>4</NO>
<PG>159-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77036977"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-08 16:09:35 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, et al</AU>
<TI>Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1980</YR>
<VL>37</VL>
<NO>1</NO>
<PG>16-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80108511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Levine J, Severe JB</AU>
<TI>Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1979</YR>
<VL>15</VL>
<NO>2</NO>
<PG>44-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="373006"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Levine J</AU>
<TI>Dosage and side effect comparisons between oral and depot fluphenazine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>29-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="329328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shafti-2009" MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Shafti 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shafti SS</AU>
<TI>Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia</TI>
<SO>Clinical Schizophrenia and Related Psychoses</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>2</NO>
<PG>97-102</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shenoy-1981" NAME="Shenoy 1981" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B</AU>
<TI>Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>3</NO>
<PG>141-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82053610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steingard-1994" NAME="Steingard 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steingard S, Allen M, Schooler NR</AU>
<TI>A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>11</NO>
<PG>470-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-1976" NAME="Stevens 1976" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens B</AU>
<TI>The social value of fluphenazine decanoate</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1976</YR>
<VL>76</VL>
<NO>5</NO>
<PG>792-804</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77178598"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-1966" NAME="Turner 1966" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner P</AU>
<TI>A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency</TI>
<SO>Journal of Pharmacy and Pharmacology</SO>
<YR>1966</YR>
<VL>18</VL>
<PG>836</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67163670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Praag-1970" NAME="Van Praag 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Praag HM, Breetveld J, van Mesdag Etty H, Westerhuis R, Pen A, Schut T</AU>
<TI>A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients</TI>
<SO>Psychiatria Neurologia Neurochirurgia</SO>
<YR>1970</YR>
<VL>73</VL>
<NO>3</NO>
<PG>165-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4912332"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vestre-1962" NAME="Vestre 1962" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vestre ND, Hall WB, Schiele BC</AU>
<TI>A comparison of fluphenazine, triflupromazine, and phenobarbital in the treatment of chronic schizophrenic patients: a double-blind controlled study</TI>
<SO>Journal of Clinical and Experimental Psychopathology</SO>
<YR>1962</YR>
<VL>23</VL>
<PG>149-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67163670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watt-1978" NAME="Watt 1978" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watt DC</AU>
<TI>Maintenance drugs for schizophrenia</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>8098</NO>
<PG>1045-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79052029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wistedt-1981" MODIFIED="2013-07-01 12:14:23 +0100" MODIFIED_BY="Heather Maxwell" NAME="Wistedt 1981" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B, Jorgensen A, Wiles D</AU>
<TI>A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency</TI>
<SO>Psychopharmacology</SO>
<YR>1982</YR>
<VL>78</VL>
<NO>4</NO>
<PG>301-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83118214"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-01 12:14:23 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B</AU>
<TI>A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1981</YR>
<VL>64</VL>
<NO>1</NO>
<PG>65-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7032224"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B</AU>
<TI>Neuroleptics and depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<NO>6</NO>
<PG>745</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6124226"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wistedt-1983" NAME="Wistedt 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wistedt B, Wiles D, Jorgensen A</AU>
<TI>A depot neuroleptic withdrawal study neurological effects</TI>
<SO>Psychopharmacology</SO>
<YR>1983</YR>
<VL>80</VL>
<NO>2</NO>
<PG>101-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4874164"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zahn-1993" MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Zahn 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zahn TP, Pickar D</AU>
<TI>Autonomic effects of clozapine in schizophrenia - comparison with placebo and fluphenazine</TI>
<SO>Biological Psychiatry</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>1-2</NO>
<PG>3-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-07-08 16:10:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-07-08 16:10:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abi_x002d_Dargham-2000" MODIFIED="2013-07-08 16:09:41 +0100" MODIFIED_BY="Heather Maxwell" NAME="Abi-Dargham 2000" TYPE="JOURNAL_ARTICLE">
<AU>Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al</AU>
<TI>Increased baseline occupancy of D2 receptors by dopamine in schizophrenia</TI>
<SO>Proceedings of the National Academy of Sciences</SO>
<YR>2000</YR>
<VL>97</VL>
<NO>14</NO>
<PG>8104-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10884434"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ahmed-1998" NAME="Ahmed 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed I, Soares K, Seifas R, Adams CE</AU>
<TI>Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>8</NO>
<PG>754-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="OLZ020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2012-05-22 13:03:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Caldwell-1992" NAME="Caldwell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell CB, Gottesman II</AU>
<TI>Schizophrenia - a high-risk factor for suicide: clues to risk reduction</TI>
<SO>Suicide and Life-Threatening Behavior</SO>
<YR>1992</YR>
<VL>22</VL>
<PG>479-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Darling-1959" NAME="Darling 1959" TYPE="JOURNAL_ARTICLE">
<AU>Darling HF</AU>
<TI>Fluphenazine: a preliminary study</TI>
<SO>Disease of the Nervous System</SO>
<YR>1959</YR>
<VL>20</VL>
<NO>4</NO>
<PG>167-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13652801"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davis-1986" NAME="Davis 1986" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Andriukatis S</AU>
<TI>The natural course of schizophrenia and effective maintenance drug therapy</TI>
<SO>Journal of Clincal Psychopharmacology</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>1Suppl</NO>
<PG>2S-10S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dencker-1980" NAME="Dencker 1980" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Lepp M, Malm U</AU>
<TI>Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study</TI>
<SO>Acta Psychiatria Scandinavica</SO>
<YR>1980</YR>
<VL>61</VL>
<NO>(supp 279)</NO>
<PG>64-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gjedde-2001" MODIFIED="2013-07-01 12:27:01 +0100" MODIFIED_BY="Heather Maxwell" NAME="Gjedde 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gjedde A, Wong DF</AU>
<TI>Quantification of neuroreceptors in living human brain v. endogenous neurotransmiter inhibition of haloperidol binding in psychosis</TI>
<SO>Journal of Cerebral Blood Flow Metabolism</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>8</NO>
<PG>982-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11487734"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hietala-1995" MODIFIED="2013-07-08 16:09:49 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hietala 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, et al</AU>
<TI>Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<NO>8983</NO>
<PG>1130-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-22 13:04:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holt-1960" NAME="Holt 1960" TYPE="JOURNAL_ARTICLE">
<AU>Holt JP, Wright ER</AU>
<TI>Preliminary results with fluphenazine (prolixin) in chronic psychotic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>157-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14402852"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1992" MODIFIED="2013-07-08 16:09:54 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jablensky 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al</AU>
<TI>Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study</TI>
<SO>Psychological Medicine Monograph Suppl.</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>4</NO>
<PG>1092</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1565705"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kane-1986" NAME="Kane 1986" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Woerner M, Sarantakos S</AU>
<TI>Depot neuroleptics: A comparison review of standard, intermediate and low-dose regimens</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>suppl 5</NO>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2012-05-22 13:03:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2012-05-22 13:03:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2012-05-22 13:03:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lindstrom-1999" MODIFIED="2013-07-08 16:09:59 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lindstrom 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, et al</AU>
<TI>Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>5</NO>
<PG>681-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10472420"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lorr-1953" NAME="Lorr 1953" TYPE="BOOK">
<AU>Lorr M</AU>
<SO>The Multidimensional Scale for Rating Psychiatric Patients</SO>
<YR>1953</YR>
<PG>19-507</PG>
<PB>U.S.V.I, , T.B</PB>
<CY>Washington D.C.</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meyer-2002" MODIFIED="2013-07-08 16:10:05 +0100" MODIFIED_BY="Heather Maxwell" NAME="Meyer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson M, Quarantelli M, et al</AU>
<TI>Reduced prefronatal activity predicts exaggerated striatal dopaminergic function in schizophrenia</TI>
<SO>Nature Neuroscience</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>3</NO>
<PG>267-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11865311"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2013-07-08 16:10:17 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials
</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>12</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychmetrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2013-07-08 16:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D</AU>
<TI>For the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010 June 1</YR>
<VL>152</VL>
<NO>11</NO>
<PG>726-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-1998" NAME="Thornley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thornley B, Adams C</AU>
<TI>Content and quality of 2000 controlled trials in schizophrenia over 50 years</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>1181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" NAME="WHO 2005" TYPE="OTHER">
<TI>Essential Medicines. WHO Model List. 14th Edition</TI>
<SO>http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wikipedia-2006" NAME="Wikipedia 2006" TYPE="OTHER">
<TI>Wikipedia (The Free Encyclopedia)</TI>
<SO>http://en.wikipedia.org/wiki/Fluphenazine#Pharmacokinetics</SO>
<YR>Accessed in Nov 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-www.psychotropics.dk" NAME="www.psychotropics.dk" TYPE="OTHER">
<TI>Psychotropics</TI>
<SO>http://www.psychotropics.dk/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2012-05-22 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-07-01 12:41:28 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Matar-2007a" MODIFIED="2013-07-01 12:41:28 +0100" MODIFIED_BY="[Empty name]" NAME="Matar 2007a" TYPE="COCHRANE_REVIEW">
<AU>Matar HE, Almerie MQ</AU>
<TI>Oral fluphenazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-04-18 03:47:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-18 03:47:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Matar-2007b" MODIFIED="2013-04-18 03:50:41 +0100" MODIFIED_BY="[Empty name]" NAME="Matar 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Matar HE-D, Almerie MQ, Giraldo AM, Adams CE</AU>
<TI>Oral fluphenazine versus placebo for schizophrenia: A Cochrane systematic review of 40 years of randomised controlled trials.</TI>
<SO>Revista Colombiana de Psiquiatria</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>1</NO>
<PG>8-17</PG>
<IDENTIFIERS MODIFIED="2013-04-18 03:48:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-1999">
<CHAR_METHODS MODIFIED="2013-03-07 11:49:31 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Blinding: double.<BR/>Duration: 6 weeks (4 weeks presented usable data).*</P>
<P>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R or RDC).<BR/>N = 53 (38 to relevant interventions).**<BR/>Age: mean 37 yrs.<BR/>Sex: M 38 (26 relevant), F 15 (12 relevant).<BR/>History: illness for ~13 yrs, clinically stable patients.<BR/>Excluded: patients with concurrent drug abuse, alcoholism, organic brain disorders and mental retardation.<BR/>Setting: community, Maryland Psychiatric Research Center Outpatient Program (US). </P>
<P>Consent: written informed consent required. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine: dose 15 mg/day, N = 18.<BR/>2. Placebo, N = 20.<BR/>[3. Diazepam: dose 30 mg/day, N = 15].</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-07 09:56:38 +0000" MODIFIED_BY="[Empty name]">
<P>Global state (CGI) - not improved or worsened.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no usable data).<BR/>Relapse (not given by each group).<BR/>Sleep change ratings (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<P>* Data were given only for the first 4 weeks of the study.<BR/>** Demographic data relate to the total of 38 people.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 13:01:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clark-1971">
<CHAR_METHODS MODIFIED="2013-03-08 14:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Blinding: double "identically appearing medication administrated from a bottle labelled only with the patient's name".<BR/>Duration: 6 weeks.</P>
<P>Design: parallel. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 13:01:51 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 76 (37 to relevant interventions).<BR/>Age: mean 33 yrs (range 18 to 45).<BR/>Sex: M 23, F 53.<BR/>History: 6 months preadmission period free of hospitalisation or shock treatment.<BR/>Excluded: childhood schizophrenia or autism, brain syndrome, IQ &lt; 70, alcoholism, recent hepatitis, chronic physical illness, epilepsy, drug addiction.<BR/>Setting: inpatient, Central State Griffin Memorial Hospital (Oklahoma, US).</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine: dose 2-10 mg/day. N = 18.<BR/>2. Placebo. N = 19.<BR/>[3. Chlorpromazine: dose 100-1000 mg/day. N = 20].<BR/>[4. Thioridazine: dose 100-1000 mg/day. N = 19].</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-08 16:30:57 +0000" MODIFIED_BY="[Empty name]">
<P>Global state (using CGI): not improved or worsened; average score (CGI severity of illness*).</P>
<P>Mental state: average score (BPRS*).<BR/>Leaving the study early: any reason; administrative/hospital transfer; AWOL; marked improvement allowing discharge.<BR/>Adverse effects: anticholinergic (dry mouth; blurred vision; nasal congestion; tachycardia; gastrointestinal distress); EPS (tremor; rigidity; associated movements; akinesia; akithisia; drooling; restlessness/ insomnia); CNS (anxiety/agitation/excitement/ confusion; sedation and lethargy; depression); cardiovascular (hypotension; syncope); others (rash).</P>
<P>Unable to use -<BR/>Global state: NOSIE (no SD).<BR/>Toxicity (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-17 13:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>Unscheduled dose adjustments were permitted for toxicity or intolerance.</P>
<P>*SDs imputed 'between groups' using RevMan calculator.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 13:04:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-1964">
<CHAR_METHODS MODIFIED="2013-03-11 12:12:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Blinding: double.<BR/>Duration: 6 weeks.</P>
<P>Design: multi-centre, parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 13:04:10 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 463 (190 to relevant interventions).<BR/>Age: 16-45 yrs.<BR/>Sex: male and female (equal distribution stated, however no number given).<BR/>History: newly admitted patients.<BR/>Excluded: childhood autism, brain syndrome, IQ &lt; 70, epilepsy, drug addiction.<BR/>Setting: inpatient, Boston State Hospital (Massachusettes); District of Columbia General Hospital (Washington DC); Kentucky State Hospital (Kentucky); Malcolm Bliss Mental Health Center (Missouri); Mercy-Dougleaa Hosptial (Pennsylvania); Payne-Whitney CLinic (New York); Rochester State Hosptial (Rochester, New York); Springfield State Hospital (Maryland); Institute of Living (Conneticut, US).</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine: dose 1-16 mg/day. N = 92.<BR/>2. Oral placebo. N = 98.<BR/>[3. Paraenteral fluphenazine. N = 23].<BR/>[4. Chlorpromazine: dose 200 mg/day. N = 112].<BR/>[5. Thioridazine: dose 200 mg/day. N = 111].<BR/>[6. Paraenteral placebo. N = 27].</P>
<P>Additional medication:<BR/>Anti-parkinsonian medications.*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-11 13:31:20 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early (any reason; treatment failure; serious complication of treatment; marked early remission; incorrect diagnosis; court cases, transfer, eloped).<BR/>Adverse effects: CNS (headache; drowsiness; convulsions or seizures) cardiovascular effects (dizziness, faintness, weakness) anticholinergic effects (increased salivation; dry mouth/throat; gastrointestinal distress and nausea; urinary disturbance; constipation; vomiting) endocrine (lactation; amenorrhoea; swelling of breasts) extrapyramidal effects (loss of associated movements; facial rigidity; rigidity; restlessness/insomnia; tremor; akithisia; dystonia) others (convulsion or seizures; diarrhoea; intercurrent infection; rash).</P>
<P>Unable to use -<BR/>Global state (no SD).**<BR/>Mental state: IMPS, WBRS (no SD).***</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-14 11:15:32 +0100" MODIFIED_BY="[Empty name]">
<P>*44% of fluphenazine group and 5% of placebo received anti-parkinsonian drugs.<BR/>**Global rating of severity of metal illness, Global rating of improvement.<BR/>***Results were not broken down by each drug group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-08 16:54:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hordern-1964">
<CHAR_METHODS MODIFIED="2013-03-07 11:49:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>Blinding: double.<BR/>Duration: 12 weeks.</P>
<P>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-01 13:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 75 (50 to relevant interventions).<BR/>Age: mean 49 yrs.<BR/>Sex: all female.<BR/>History: hospitalisation &gt; 2 yrs (mean ~20 yrs, ~SD 9), all have had previous unsuccessful phenothiazines treatment, and none leucotomised.<BR/>Excluded: physical illness, epilepsy.<BR/>Setting: inpatient, Mont Park Hospital, Victoria (Australia).</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 13:06:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine: dose &lt; 14 mg/day. N = 25.<BR/>2. Placebo. N = 25.<BR/>[3. Thioproperazine (max dose of 140 mg/day). N = 25].</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-08 16:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: MADRS* - not improved or worsened.<BR/>Adverse effects - extrapyramidal effects: dystonia; akinesia; parkinsonism; akathisia.<BR/>Leaving study early.**</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-07 10:16:09 +0000" MODIFIED_BY="[Empty name]">
<P>* Rated as either 'no change', 'clear worsening' and 'marked worsening' using the Multidimensional Rating Scale of the Veterans' Administration (<LINK REF="REF-Lorr-1953" TYPE="REFERENCE">Lorr 1953</LINK>).<BR/>** Two participants from fluphenazine group left the study early and they were considered to have the worst outcomes.<BR/>The ward sister's blind ratings of change of behaviour at the end of the trial: 9 placebo participants deteriorated in contrast to 6 participants on fluphenazine. One placebo participant required additional nursing care because of severe negativism.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marder-1994">
<CHAR_METHODS MODIFIED="2013-03-07 11:49:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomly assigned.<BR/>Blindness: double.<BR/>Duration: 2 years (preceded by 2 months stabilisation phase with low dose of fluphenazine decanoate 5-10 mg).</P>
<P>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N = 36.<BR/>Age: mean 40 yrs.<BR/>Sex: all male.<BR/>History: at least two documented episodes of acute schizophrenic illness or at least 2 years of continuing psychotic symptoms, randomly assigned when getting prodromal symptoms using Idiosyncratic Prodromal Scale.<BR/>Excluded: patients who could not be stabilised for 2 or more months with 10 mg or less of fluphenazine decanoate every 2 weeks.<BR/>Setting: community, outpatients at Brentwood Division of West Los Angeles Verterans Affairs Medical Center (US).</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine hydrochloride: dose 10 mg/day. N = 17.<BR/>2. Placebo. N = 19.</P>
<P>Additional medication -<BR/>Fluphenazine decanoate: dose 5-10 mg/2weeks for all patients. N = 36.</P>
<P>Factored to:<BR/>A. Behavioural skills training.<BR/>B. Supportive group therapy.**</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 12:50:50 +0000" MODIFIED_BY="[Empty name]">
<P>Relapse: defined as number of psychotic exacerbations.*<BR/>Percentage of time in exacerbated state (skew).<BR/>Percentage of time in prodrome (skew).<BR/>Leaving the study early: non-specific reasons.</P>
<P>Unable to use -<BR/>Adverse effects (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-07 11:32:44 +0000" MODIFIED_BY="[Empty name]">
<P>* Defined as worsening of four points or more on the sum of the BPRS clusters for thought disturbance and paranoia or increase of three or more points on either cluster.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Millar-1963">
<CHAR_METHODS MODIFIED="2013-03-11 13:04:13 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Blindness: double.<BR/>Duration: 6 weeks.</P>
<P>Design: cross-over (after 3 weeks).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 38.<BR/>Age: 28-58 yrs (mean 46 yrs).<BR/>Sex: all female.<BR/>Excluded: advanced age, doubtful diagnostic classification, epilepsy, severe sub-normality.<BR/>History: in hospital 2-35 yrs (mean 18 yrs).<BR/>Setting: inpatient, UK.</P>
<P>Consent: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine: dose 2.5 mg/day. N = 19.<BR/>2. Placebo. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-07 12:06:30 +0000" MODIFIED_BY="[Empty name]">
<P>Relapse.</P>
<P>Unable to use -</P>
<P>Improvement: no better or worse (data not reported by group). <BR/>Adverse effects (no data).</P>
<P>Lorr psychiatric rating scale (no SD, mean only).</P>
<P>Baker and Thorpe behaviour rating scale (no SD, mean only).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-07 11:51:06 +0000" MODIFIED_BY="[Empty name]">
<P>Participants had been receiving chlorpromazine three times a day and were "mostly stabilised" on a certain dose. They were then given doses of fluphenazine, with this drug substituted for the chlorpromazine at approx. one fortieth of the dose. A single daily dose was given of 2.5 mg (with the exception of two cases who received 20 mg) with dose increase of 2.5 mg/day (one tablet). After participants received fluphenazine for 2 months, they were rated and randomised into intervention groups, receiving dosages established in the stabilisation phase. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rifkin-1976">
<CHAR_METHODS MODIFIED="2013-03-11 14:50:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Blindness: double.<BR/>Duration: 1 year (preceded by several months transitional period during which all patients were treated exclusively with fluphenazine decanoate and oral fluphenazine).</P>
<P>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (remitted).<BR/>N = 73 (50 to relevant interventions).<BR/>Sex: M 50 , F 23.<BR/>Age: 17-40 yrs.<BR/>History: reached a stable remission while receiving FD and FPZ and showed no adverse effects.<BR/>Excluded: history of severe drug abuse or chronic schizophrenics.*<BR/>Setting: psychiatric aftercare clinic, Long Island Jewish-Hillside Medican Center (US).</P>
<P>Consent: informed consent obtained.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Oral fluphenazine: dose 5-20 mg/day. N = 28.<BR/>2. Placebo. N = 22.<BR/>[3. Fluphenazine decanoate: dose 0.5-2.0 mL/2weeks. N = 23].</P>
<P>Additional medication:<BR/>Prophylactic procyclidine (5-15 mg/day).**<BR/>Placebo procyclidine.<BR/>Psychotherapy biweekly during the first 6months and monthly thereafter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-11 14:52:23 +0000" MODIFIED_BY="[Empty name]">
<P>Death.<BR/>Relapse (clinical judgement).<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Social and vocational functioning (results not broken down by individual drugs).<BR/>Mental state: BPRS (no data).<BR/>Global state: CGI, PER-C (no data).<BR/>KAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-11 13:06:15 +0000" MODIFIED_BY="[Empty name]">
<P>* Chronic patients &gt; 3 previous hospitalisations.<BR/>** Prophylactic procyclidine for patients receiving active treatment and in the first 2 months for patients receiving placebo to prevent the emergence of extrapyramidal side effects during the fluphenazine decanoate washout period.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RDC - Research Diagnostic Criteria for schizophrenia or schizoaffective disorders<BR/>DSM - Diagnostic and Statistical Manual<BR/>FD - Fluphenazine Decanoate<BR/>FPZ - Oral fluphenazine</P>
<P>
<B>Rating</B> <B>Scales</B>:<BR/>KAS- Katz Adjustment Scale</P>
<P>
<I>Global state:</I>
<BR/>CGI - Clinical Global Impression<BR/>NOSIE - Nurse's Observation Scale for Inpatient Evaluation</P>
<P>
<I>Mental state:</I>
<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale<BR/>MADRS - modified Montgomery-Asberg Depression Rating Scale<BR/>PER-C - Periodic Evaluation Record-Community<BR/>WBRS - Burdock Ward Behaviour Rating Scale</P>
<P>Other:<BR/>CNS - central nervous system<BR/>EPS - extrapyramidal symptoms<BR/>ITT - intention-to-treat<BR/>LOCF - last observation carried forward<BR/>SD - standard deviation<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-07-08 16:12:06 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-03-01 12:02:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 12:02:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with non-organic psychosis (schizophrenia, schizoaffective disorder, unipolar disorder, bipolar disorder or a delusional disorder).<BR/>Interventions: vitamin E versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baladini-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia. <BR/>Interventions: amitriptyline and fluphenazine (combination tablets) versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-01 16:13:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boyer-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 16:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: amisulpride versus fluphenazine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breier-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear. <BR/>Participants: people with schizophrenia.<BR/>Interventions: fluphenazine versus placebo (withdrawal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carpenter-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: diazepam versus depot fluphenazine versus placebo. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chacon-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: depot fluphenazine versus chlorpromazine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chacon-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: depot fluphenazine versus chlorpromazine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coffman-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: depot fluphenazine versus placebo (oral fluphenazine as a background).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Del-Giudice-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: oral phenothiazine versus phenothiazine enanthate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doran-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dowing--1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: fluphenazine versus chlorpromazine versus thioridazine versus placebo. <BR/>Outcomes: mental state (no SD).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haider-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine versus fluphenazine enanthate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-17 15:05:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanlon-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-10 03:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
<P>Participants: newly admitted patients to psychiatric wards, alcoholics, drug addicts, psychosis. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Held-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: phenothiazines versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hogarty-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine versus fluphenazine decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holden-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-17 15:05:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howell-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-10 03:50:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear. </P>
<P>Participants: people with functional psychosis. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Itil-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine low dose versus high dose.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Itil-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia.<BR/>Interventions: fluphenazine versus haloperidol versus thiothixene.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kane-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine, fluphenazine decanoate versus placebo.<BR/>Outcomes: results are not broken down by individual drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-17 15:05:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinross_x002d_Wright-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 13:22:29 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinross_x002d_Wright-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: first stage - oral fluphenazine versus fluphenazine enanthate, second stage - fluphenazine enanthate versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leff-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: trifluoperazine versus chlorpromazine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Litman-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marder-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine versus fluphenazine decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-17 15:05:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marder-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-10 03:52:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. </P>
<P>Participants: people with schizophrenia. </P>
<P>Interventions: intensive behavioural skills training versus supportive group psychotherapy. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia. <BR/>Interventions: benzhexol versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-17 15:05:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matheu-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 13:23:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattes-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine versus fluphenazine decanoate versus lithium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pichot-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine versus amisulpride and haloperidol versus amisulpride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pickar-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: oral fluphenazine versus placebo (withdrawal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pickar-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quitkin-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine decanoate versus penfluridol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sampath-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine decanoate versus placebo (withdrawal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schlosberg-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia. <BR/>Interventions: pipotiazine palmitate versus fluphenazine decanoate versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schooler-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia.<BR/>Interventions: fluphenazine decanoate versus oral fluphenazine, oral fluphenazine versus placebo (withdrawal study), fluphenazine decanoate versus placebo (withdrawal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-18 15:04:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shafti-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 14:48:30 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: fluphenazine decanoate (IM) versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shenoy-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine decanoate versus placebo (withdrawal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steingard-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine versus placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stevens-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine decanoate versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turner-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: chlorpromazine versus fluphenazine versus placebo. <BR/>Outcomes: critical flicker fusion frequency (no usable data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Praag-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: oral fluphenazine versus fluphenazine decanoate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vestre-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine versus triflupromazine versus phenobarbital.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Watt-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine versus oral pimozide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wistedt-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: fluphenazine decanoate or flupentixol decanoate versus placebo (withdrawal study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wistedt-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with schizophrenia. <BR/>Interventions: fluphenazine decanoate, flupenthixol decanoate versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-01 12:57:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zahn-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 15:16:09 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: clozapine versus conventional neuroleptics including oral fluphenazine and placebo.</P>
<P>Outcomes: no useable data - results not presented for individual groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>IM - intramuscular<BR/>SD - standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-07-10 03:37:51 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-06-14 11:10:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:10:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>Random - "a stratified randomization procedure...was used to assign drug treatment to balance study groups on gender, prior social function, and past duration of hospital care" (p300). No details as to randomisation methods. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-08 12:00:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-1971">
<DESCRIPTION>
<P>Random: "patients were assigned to treatment randomly in blocks of four" (p404) - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 10:34:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1964">
<DESCRIPTION>
<P>Random: participants were "randomly assigned to one of four treatments on a double-blind basis" (p247). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 09:10:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hordern-1964">
<DESCRIPTION>
<P>Randomisation unclear - participants were "divided into three groups of 25 matched on age, chronicity and severity of illness" (p532).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 10:52:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>Random - possible participants were stabilised on low dose fluphenazine decanoate (5 to 10 mg every 14 days) for two months and monitored every week using an idiosyncratic prodromal rating scale. Participants were randomised to either oral fluphenazine or placebo when they met criteria for a prodromal episode. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 11:47:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millar-1963">
<DESCRIPTION>
<P>Random - participants were divided into two random groups; no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 14:50:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1976">
<DESCRIPTION>
<P>Random: "randomly assigned" (p44). 15% of patients referred schizophrenics were re-diagnosed using Kraepelinian Criteria as non schizophrenic and randomised separately but treated in the same manner.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-03-11 14:54:34 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-06 15:31:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-08 11:59:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clark-1971">
<DESCRIPTION>
<P>Participants were "assigned to treatment randomly in blocks of four" (p404) - no further details. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 12:21:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1964">
<DESCRIPTION>
<P>Stratified by sex with "randomized assignment to drug treatment within each sex group" (p247). In the three out of nine hospitals participating in the study that admitted approximately equal number of White and Black participants, this was taken into account and groups were further stratified by race. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 09:10:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hordern-1964">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 10:57:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 11:46:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millar-1963">
<DESCRIPTION>
<P>Only hospital pharmacist knew the composition of the groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 14:54:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1976">
<DESCRIPTION>
<P>"Randomly assigned" (p44) - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-06-14 11:17:08 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:16:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>Double blind - no further details. If participants experienced worsening or exacerbation of symptoms, they were removed from the study and treated on an open basis with fluphenazine.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:13:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-1971">
<DESCRIPTION>
<P>Double blind: "double blind design was maintained throughout the study" (p404) - no further details. Identically-appearing capsules were dispensed from a bottle labelled only with the participant name.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:13:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1964">
<DESCRIPTION>
<P>Double blind described, no further details. Participants received individually numbered containers of medication. A flexile dosage schedule permitted the treating physician to adjust dosage according to individuals' needs.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:14:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hordern-1964">
<DESCRIPTION>
<P>Double blind (implied) - members of the ward staff were told that powerful phenothiazine drugs were to be administered, but were unaware of which participants were receiving the active medication. All medications were identical-looking tablets, dispensed by a medical officer who "took no part in the rating procedure" (p533). Maximum blindness preserved in evaluations claimed, as neither physicians entered the closed wards between ratings and did not observe side effects during period of treatment. A blind assessment of overall change was made at the end of the trial by the ward sister.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:14:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>Double blind (implied), as participants who never experienced prodromal episodes nor were assigned to either treatment were treated with 5 mg oral fluphenazine on an open label basis during exacerbations.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:17:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Millar-1963">
<DESCRIPTION>
<P>Double blind - only hospital pharmacist knew the composition of the groups; medication was administered with matching placebo.</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-14 11:17:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rifkin-1976">
<DESCRIPTION>
<P>Double blind: drugs were given in a "double blind fashion" (p44).</P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-09 13:58:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>No mention of participants lost to follow-up or leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-08 16:12:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clark-1971">
<DESCRIPTION>
<P>Follow-up: 85% - n = 2 participants left the study early, but their final measures were obtained and used in the analysis (n = 1 receiving placebo due to behavioural deterioration and n = 1 receiving fluphenazine was discharged from the hospital as markedly improved after two weeks). A further n = 11 participants, however, were dropped without final measures being obtained (placebo: n = 1 went AWOL; n = 1 on convalescent leave; n = 1 transferred to another hospital. Thioridazine group: n = 2 AWOL; n = 1 medication intolerance. Chlorpromazine: n = 1 AWOL; n = 2 refused oral medication. Fluphenazine: n = 1 administrative transfer, n = 1 AWOL). Dichotomised data presented as ITT (only n = 1 missing from placebo). LOCF for CGI and BPRS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-11 12:59:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldberg-1964">
<DESCRIPTION>
<P>Follow-up: 74%. Reasons for removal of study included administrative removals (incorrect diagnoses; intercurrent medical illness; court cases, transfer, elopement, etc), treatment-related removals (marked early remission; serious complication of treatment; treatment failure). Those lost were not included in the study report analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-01 13:07:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hordern-1964">
<DESCRIPTION>
<P>Follow-up: 95% - n = 4 participants were lost to follow-up by 12 weeks of treatment, only n = 2 were accounted for as having discontinued from active drugs (n = 1 from fluphenazine; n = 1 from thioproperazine). ITT used for medium-term data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>Follow-up: 81% - n = 6 participants lost to follow-up by two years of treatment. Only two participants accounted for as being omitted from analysis (n = 1 who dropped-out during a prodromal episode, and n = 1 who reached the two-year end point during a prodrome). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millar-1963">
<DESCRIPTION>
<P>No mention of participants lost to follow-up or leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-13 14:46:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1976">
<DESCRIPTION>
<P>Follow-up: 89%. Drop-outs mainly due to moving from the geographical area or refusing further care. None of these patient's conditions had deteriorated clinically.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 09:05:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>No scale data reported for BPRS or CGI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-08 15:21:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clark-1971">
<DESCRIPTION>
<P>No SDs reported for all scale data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 12:21:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldberg-1964">
<DESCRIPTION>
<P>No SDs reported for continuous data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 10:03:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hordern-1964">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-07 11:27:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>None detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-09 13:58:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Millar-1963">
<DESCRIPTION>
<P>Data not clearly described as to the stage of trial and relevant groups (i.e. pre-cross-over or post-cross-over). Full data not reported for continuous outcomes (missing means and SDs).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 15:09:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rifkin-1976">
<DESCRIPTION>
<P>Not all adverse effects reported by group. No data reported for individual groups using the BPRS, CGI, PER-C, KAS scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-14 11:14:32 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:13:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1999">
<DESCRIPTION>
<P>Funding: supported in part by NIMH grants (MH-35996 and MH-40279).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:13:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clark-1971">
<DESCRIPTION>
<P>Funding: supported in part by Public Health Service Grant MH 11666 and Research Scientist Development award No. K135278 from NIMH. Medication supplied by Smith Kline and French Laboratories (chlorpromazine and placebo); Sandoz Inc (thioridazine) and ER Squibb &amp; Sons (fluphenazine).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-11 12:47:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1964">
<DESCRIPTION>
<P>Funding: supported by NIMH grants (MH 04661, 04663, 04667, 04673, 04674, 04675, 04679, 04803). Medications provided free of charge from Sandoz Pharmaceuticals (Hanover); Squibb Institute for Medical Research (New Brunswick); Smith Kline and French Laboratories (Philiadelphia). </P>
<P>Rating scales: raters not stated to be independent of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hordern-1964">
<DESCRIPTION>
<P>Funding: all drugs and placebos were provided free of charge by May and Baker (Australia) Limited ('Majeptil') and ER Squibb and Sons (Australia) Limited ('Anatensol').</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:14:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>Funding: study supported by the Medical Research Service of the Department of Veterans Affairs, Washington DC (grant MH-41573) from National Institute of Mental Health, Bethesda, Md; UCLA Mental Health Clinical Research Center for Schizophrenia (grant MH-30911) from the National Institute of Mental Health.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Millar-1963">
<DESCRIPTION>
<P>Funding: fluphenazine tablets were provided by ER Squibb &amp; Sons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-14 11:14:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1976">
<DESCRIPTION>
<P>Funding: supported by NIMH grant MH 21337-03.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-06-13 10:51:41 +0100" MODIFIED_BY="Grade Profiler">ORAL FLUPHENAZINE versus PLACEBO for Schizophrenia</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>ORAL FLUPHENAZINE versus PLACEBO for Schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with Schizophrenia<BR/>
<B>Settings:</B> inpatient and outpatient (Australia and US)<BR/>
<B>Intervention:</B> ORAL FLUPHENAZINE versus PLACEBO<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ORAL FLUPHENAZINE versus PLACEBO</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: Not improved or worsened - medium term</B>
<BR/>Dichotomised Montgomery-Asberg Depression Rating Scale (MDRS)<BR/>Follow-up: 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>680 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>762 per 1000</B>
<BR/>(537 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.12 </B>
<BR/>(0.79 to 1.58)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Global state: Relapse - long term</B>
<BR/>Clinical judgement<BR/>Follow-up: 52 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.39 </B>
<BR/>(0.05 to 3.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>86<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>Note: high degree of heterogeneity between included studies.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 1000</B>
<BR/>(10 to 662)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>234 per 1000</B>
<BR/>(30 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>312 per 1000</B>
<BR/>(40 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Death - long term</B>
<BR/>Occurrences of death<BR/>Follow-up: 52 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>7</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.38 </B>
<BR/>(0.1 to 55.72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
<BR/>(3 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>214 per 1000</B>
<BR/>(9 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal effects (akathisia) - short term</B>
<BR/>Instances of akathisia<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>8</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 3.43 </B>
<BR/>(1.23 to 9.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>227<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>8</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>343 per 1000</B>
<BR/>(123 to 956)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>8</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>686 per 1000</B>
<BR/>(246 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal effects (rigidity) - short term</B>
<BR/>Instances of rigidity<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>10</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 3.54 </B>
<BR/>(1.76 to 7.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>227<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>177 per 1000</B>
<BR/>(88 to 357)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>10</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>885 per 1000</B>
<BR/>(440 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>10</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(880 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Mean baseline risk presented for single study.<BR/>
<SUP>2</SUP> Risk of bias: rated 'very serious' (downgraded by 2 points) - randomisation unclear, with no mention or description of methods. Raters of scales not stated to be independent of treatment.<BR/>
<SUP>3</SUP> Imprecision: rated 'serious' (downgraded by 1 point) - 95% confidence intervals for best estimate of effect include both 'no effect' and appreciable benefit/harm.<BR/>
<SUP>4</SUP> Low risk: equates to intervention group (11%) in one study with a higher risk in the other included study (71%); high risk in the control group (74%).<BR/>
<SUP>5</SUP> Risk of bias: rated 'serious' (downgraded by 1 point) - lack of information for participants leaving the study early. Not all adverse effects data reported, and data not reported for various rating scales by intervention group.<BR/>
<SUP>6</SUP> Imprecision: rated 'very serious' (downgraded by 2 points) - only two small studies presented data on this outcome, with considerable heterogeneity present (P = 0.0003; I2 = 92%).<BR/>
<SUP>7</SUP> Low risk: equates to control group (0%), with a moderate risk in the intervention group (3.6%).<BR/>
<SUP>8</SUP> Low risk: equates to control group (3.4%), with a moderate risk in the intervention group (12.7%).<BR/>
<SUP>9</SUP> Risk of bias: rated 'serious' (downgraded by 1 point) - one of the two included studies did not: provide details of randomisation; report SDs for continuous outcomes; account for participants lost to follow-up.<BR/>
<SUP>10</SUP> Low risk: equates to control group (7.7%), with a moderate risk in the intervention group (27.3%).</P>
<P>Key: </P>
<P>
<I>High quality </I>- no downgrading of the evidence.<BR/>
<I>Moderate quality </I>- evidence downgraded by 1 point ('serious').<BR/>
<I>Low quality </I>- evidence downgraded by 1 point twice ('serious') or 2 points ('very serious').<BR/>
<I>Very low quality </I>- evidence downgraded any further than listed above.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-07-09 14:23:12 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-07-09 14:23:12 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ORAL FLUPHENAZINE versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="2.657865633346772" CI_END="1.1535792732097936" CI_START="0.7005014286845164" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8989348858422986" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="54" I2="0.0" I2_Q="46.93431912075938" ID="CMP-001.01" LOG_CI_END="0.062047444314084176" LOG_CI_START="-0.15459097462635918" LOG_EFFECT_SIZE="-0.0462717651561375" METHOD="MH" MODIFIED="2013-03-15 16:56:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44743519719096636" P_Q="0.16982864536370368" P_Z="0.40244825226540804" Q="1.8844571169748274" RANDOM="NO" SCALE="10.21" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="89" WEIGHT="200.0" Z="0.8372567862218107">
<NAME>Global state: 1. Not improved or worsened</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8079526174273597" CI_END="1.1160598158245412" CI_START="0.5673140160349429" DF="2" EFFECT_SIZE="0.7957112392386066" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.047687471471069234" LOG_CI_START="-0.24617648664252575" LOG_EFFECT_SIZE="-0.0992445075857283" MODIFIED="2013-03-15 16:56:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6676601837028485" P_Z="0.1855534091046641" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="64" WEIGHT="100.0" Z="1.3238483669797192">
<NAME>short term (CGI/MDRS)</NAME>
<DICH_DATA CI_END="1.3124918683512852" CI_START="0.4799127502814732" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756292" MODIFIED="2013-03-15 16:56:20 +0000" MODIFIED_BY="[Empty name]" ORDER="16757" O_E="0.0" SE="0.2566573900611784" STUDY_ID="STD-Carpenter-1999" TOTAL_1="18" TOTAL_2="20" VAR="0.06587301587301587" WEIGHT="36.821736039807284"/>
<DICH_DATA CI_END="1.4179145657902803" CI_START="0.24253092189533307" EFFECT_SIZE="0.5864197530864198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.15165006390513358" LOG_CI_START="-0.6152328824126999" LOG_EFFECT_SIZE="-0.23179140925378314" MODIFIED="2013-03-15 16:41:58 +0000" MODIFIED_BY="[Empty name]" ORDER="16758" O_E="0.0" SE="0.4504708387989029" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.20292397660818712" WEIGHT="24.310875918173917"/>
<DICH_DATA CI_END="1.550082129088543" CI_START="0.5562575567955155" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2013-03-15 16:56:20 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.26144148169647513" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.06835164835164834" WEIGHT="38.867388042018796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.58223241928318" CI_START="0.7894762696512048" DF="0" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.1992702787812681" LOG_CI_START="-0.10266091963215801" LOG_EFFECT_SIZE="0.048304679574555046" NO="2" P_CHI2="1.0" P_Z="0.5305723945644689" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.6271324907685691">
<NAME>medium term (MDRS)</NAME>
<DICH_DATA CI_END="1.58223241928318" CI_START="0.7894762696512048" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.1992702787812681" LOG_CI_START="-0.10266091963215801" LOG_EFFECT_SIZE="0.048304679574555046" ORDER="16759" O_E="0.0" SE="0.17735588053158297" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.03145510835913313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.72264660781031" CI_END="1.6809376182017948" CI_START="0.07222546995419957" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34843436891087187" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="38" I2="88.04017063264436" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.22555159650107917" LOG_CI_START="-1.1413096236221993" LOG_EFFECT_SIZE="-0.45787901356056004" METHOD="MH" MODIFIED="2013-06-13 16:44:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.3373632024870084E-4" P_Q="0.7260506264578976" P_Z="0.18914252877412993" Q="0.1227689193397046" RANDOM="YES" SCALE="367.2935247612345" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.662008244225301" TOTALS="YES" TOTAL_1="64" TOTAL_2="60" WEIGHT="100.00000000000003" Z="1.3131199607440545">
<NAME>Global state: 2. Relapse</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0270576804649376" CI_START="0.06085344687915381" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.011594834643236494" LOG_CI_START="-1.2157148172991612" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-06-13 15:42:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05448871361546994" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="29.547452401633304" Z="1.9229310185375879">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.0270576804649376" CI_START="0.06085344687915381" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.011594834643236494" LOG_CI_START="-1.2157148172991612" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-06-13 15:42:13 +0100" MODIFIED_BY="[Empty name]" ORDER="16760" O_E="0.0" SE="0.7209277648317224" STUDY_ID="STD-Millar-1963" TOTAL_1="19" TOTAL_2="19" VAR="0.5197368421052633" WEIGHT="29.547452401633304"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.23302051952571" CI_END="3.3123251452558877" CI_START="0.04702289047405401" DF="1" EFFECT_SIZE="0.3946582097458795" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" I2="92.44314630567926" ID="CMP-001.02.02" LOG_CI_END="0.5201329615245384" LOG_CI_START="-1.3276906785213922" LOG_EFFECT_SIZE="-0.403778858498427" MODIFIED="2013-06-13 16:44:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.7506489991468985E-4" P_Z="0.39168445145841624" STUDIES="2" TAU2="2.185894340470836" TOTAL_1="45" TOTAL_2="41" WEIGHT="70.45254759836672" Z="0.8565666151515848">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.3137411824938359" CI_START="0.6085265328018733" EFFECT_SIZE="0.8941176470588236" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.11850981416884122" LOG_CI_START="-0.21572048103584393" LOG_EFFECT_SIZE="-0.04860533343350136" MODIFIED="2013-06-13 16:44:59 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.1963285298698762" STUDY_ID="STD-Marder-1994" TOTAL_1="17" TOTAL_2="19" VAR="0.03854489164086687" WEIGHT="37.90825921944202"/>
<DICH_DATA CI_END="0.4752550737842256" CI_START="0.051959208671661386" EFFECT_SIZE="0.15714285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.3230732379454667" LOG_CI_START="-1.284337471766597" LOG_EFFECT_SIZE="-0.8037053548560318" ORDER="16762" O_E="0.0" SE="0.5646513692812307" STUDY_ID="STD-Rifkin-1976" TOTAL_1="28" TOTAL_2="22" VAR="0.3188311688311688" WEIGHT="32.54428837892469"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.03" MODIFIED="2013-07-08 16:11:11 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Global state: 3. Percentage of time in prodrome state (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.03.01" MODIFIED="2013-07-08 16:11:07 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>one-year data</NAME>
<OTHER_DATA MODIFIED="2013-03-14 12:42:22 +0000" MODIFIED_BY="[Empty name]" ORDER="126" STUDY_ID="STD-Marder-1994">
<TR>
<TD>
<P>Oral fluphenazine</P>
</TD>
<TD>
<P>10.5</P>
</TD>
<TD>
<P>15.90</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>19.4</P>
</TD>
<TD>
<P>22.30</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.03.02" MODIFIED="2013-07-08 16:11:11 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>two-year data</NAME>
<OTHER_DATA MODIFIED="2013-03-07 11:09:34 +0000" MODIFIED_BY="[Empty name]" ORDER="127" STUDY_ID="STD-Marder-1994">
<TR>
<TD>
<P>Oral fluphenazine</P>
</TD>
<TD>
<P>2.80</P>
</TD>
<TD>
<P>3.80</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>4.90</P>
</TD>
<TD>
<P>5.70</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.04" MODIFIED="2013-07-09 14:23:12 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Global state: 4. Percentage of time in exacerbated state (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.04.01" MODIFIED="2013-07-09 14:23:04 +0100" MODIFIED_BY="Heather Maxwell" NO="1" STUDIES="1">
<NAME>one-year data</NAME>
<OTHER_DATA ORDER="128" STUDY_ID="STD-Marder-1994">
<TR>
<TD>
<P>Oral fluphenazine</P>
</TD>
<TD>
<P>11.8</P>
</TD>
<TD>
<P>15.00</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>7.20</P>
</TD>
<TD>
<P>10.70</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.04.02" MODIFIED="2013-07-09 14:23:12 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>two-year data</NAME>
<OTHER_DATA MODIFIED="2013-03-07 11:09:05 +0000" MODIFIED_BY="[Empty name]" ORDER="129" STUDY_ID="STD-Marder-1994">
<TR>
<TD>
<P>Oral fluphenazine</P>
</TD>
<TD>
<P>5.50</P>
</TD>
<TD>
<P>10.40</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P>13.6</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.14934473822898287" CI_START="-1.390655261771017" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.77" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2013-06-18 15:05:25 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.015033171748550931" Q="0.0" RANDOM="NO" SCALE="6.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="2.431578947368421">
<NAME>Global state: 5. average score: CGI - severity of illness score (high = poor)</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14934473822898287" CI_START="-1.390655261771017" DF="0" EFFECT_SIZE="-0.77" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2013-03-08 15:34:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.015033171748550931" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="2.431578947368421">
<NAME>short term</NAME>
<CONT_DATA CI_END="-0.14934473822898287" CI_START="-1.390655261771017" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.77" MODIFIED="2013-03-08 15:33:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1187" SD_1="0.95" SD_2="0.95" SE="0.31666666666666665" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.9812510476390206" CI_END="1.0997044048924967" CI_START="0.48786585019472833" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7324672173249569" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.04127596463472789" LOG_CI_START="-0.31169958072161513" LOG_EFFECT_SIZE="-0.13521180804344363" METHOD="MH" MODIFIED="2013-03-15 16:36:55 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7392076109225842" P_Q="0.4321712825979164" P_Z="0.13320595675805144" Q="1.6778678011589547" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="180" TOTAL_2="183" WEIGHT="100.0" Z="1.50157866478911">
<NAME>Leaving the study early: 1. Non-specific reasons</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11328293243727344" CI_END="1.0681188881381654" CI_START="0.43283335066042117" DF="1" EFFECT_SIZE="0.6799393188046458" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="36" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.028619595004109308" LOG_CI_START="-0.36367928336876104" LOG_EFFECT_SIZE="-0.1675298441823259" MODIFIED="2013-03-08 16:07:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7364371234550844" P_Z="0.09413230294518504" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="82.03684934522377" Z="1.67399133178696">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.5373250023253373" CI_START="0.10978072673416774" EFFECT_SIZE="0.5277777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40437609894284754" LOG_CI_START="-0.9594738985717641" LOG_EFFECT_SIZE="-0.2775488998144583" MODIFIED="2013-03-08 16:07:51 +0000" MODIFIED_BY="[Empty name]" ORDER="16767" O_E="0.0" SE="0.801132239706452" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.6418128654970761" WEIGHT="9.15326976251681"/>
<DICH_DATA CI_END="1.119804357362598" CI_START="0.4363881776439945" EFFECT_SIZE="0.6990489130434783" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="32" LOG_CI_END="0.04914215308113872" LOG_CI_START="-0.3601270235592329" LOG_EFFECT_SIZE="-0.15549243523904713" ORDER="16768" O_E="0.0" SE="0.2404067402736522" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.05779540076900326" WEIGHT="72.88357958270696"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.16103229177347" CI_START="0.25211516482038504" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="1.9963410392362373" LOG_CI_START="-0.5984010305641998" LOG_EFFECT_SIZE="0.6989700043360189" NO="2" P_CHI2="1.0" P_Z="0.2909920990722461" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.1759409069900069" Z="1.055947757364389">
<NAME>medium term</NAME>
<DICH_DATA CI_END="99.16103229177347" CI_START="0.25211516482038504" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9963410392362373" LOG_CI_START="-0.5984010305641998" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="16769" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="1.1759409069900069"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18118401949904583" CI_END="1.9724778092524298" CI_START="0.2415283903260186" DF="1" EFFECT_SIZE="0.6902241594022416" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.29501212601406646" LOG_CI_START="-0.6170318129983768" LOG_EFFECT_SIZE="-0.16100984349215516" NO="3" P_CHI2="0.6703576872186022" P_Z="0.4889286696800741" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="41" WEIGHT="16.78720974778623" Z="0.692013796490455">
<NAME>long term</NAME>
<DICH_DATA CI_END="3.221700501916365" CI_START="0.21809550822199264" EFFECT_SIZE="0.8382352941176471" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5080851647577107" LOG_CI_START="-0.6613532788252005" LOG_EFFECT_SIZE="-0.07663405703374492" ORDER="16770" O_E="0.0" SE="0.6869339305742584" STUDY_ID="STD-Marder-1994" TOTAL_1="17" TOTAL_2="19" VAR="0.4718782249742001" WEIGHT="8.884886852813384"/>
<DICH_DATA CI_END="2.8668073567393826" CI_START="0.09570800653505623" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4573985102760918" LOG_CI_START="-1.0190517294274801" LOG_EFFECT_SIZE="-0.2808266095756942" ORDER="16771" O_E="0.0" SE="0.8672741793484354" STUDY_ID="STD-Rifkin-1976" TOTAL_1="28" TOTAL_2="22" VAR="0.7521645021645021" WEIGHT="7.902322894972846"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.294007733117912" CI_END="1.2545813096244942" CI_START="0.45868504063860444" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7585892689654559" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" I2="68.60142831294775" I2_Q="68.59944051581736" ID="CMP-001.07" LOG_CI_END="0.09849881326076884" LOG_CI_START="-0.33848542353500494" LOG_EFFECT_SIZE="-0.11999330513711803" METHOD="MH" MODIFIED="2013-03-15 16:37:03 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0022601786315261663" P_Q="0.002261449047428976" P_Z="0.2817532469258227" Q="22.292596421812483" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="521" TOTAL_2="553" WEIGHT="800.0" Z="1.076389199661634">
<NAME>Leaving the study early: 2. Specific reason - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.640507378231115" CI_START="0.07123794029949233" DF="0" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2013-03-08 16:10:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9686438170932244" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.039309268549162925">
<NAME>administrative/hospital transfer</NAME>
<DICH_DATA CI_END="15.640507378231115" CI_START="0.07123794029949233" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2013-03-08 16:10:10 +0000" MODIFIED_BY="[Empty name]" ORDER="16772" O_E="0.0" SE="1.3754318832632446" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="1.891812865497076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.640507378231115" CI_START="0.07123794029949233" DF="0" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2013-03-08 16:10:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9686438170932244" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.039309268549162925">
<NAME>AWOL</NAME>
<DICH_DATA CI_END="15.640507378231115" CI_START="0.07123794029949233" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2013-03-08 16:10:17 +0000" MODIFIED_BY="[Empty name]" ORDER="16772" O_E="0.0" SE="1.3754318832632446" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="1.891812865497076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.58175350770325" CI_START="1.3908601396145508" DF="0" EFFECT_SIZE="10.652173913043478" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="1.911593035751059" LOG_CI_START="0.1432834609428202" LOG_EFFECT_SIZE="1.0274382483469395" MODIFIED="2013-03-08 16:10:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.022751026242344524" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="2.277589842623906">
<NAME>court cases, transfer, eloped</NAME>
<DICH_DATA CI_END="81.58175350770325" CI_START="1.3908601396145508" EFFECT_SIZE="10.652173913043478" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.911593035751059" LOG_CI_START="0.1432834609428202" LOG_EFFECT_SIZE="1.0274382483469395" ORDER="16773" O_E="0.0" SE="1.0387137975159257" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="1.0789263531499558" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.7826372517289" CI_START="0.06761083337008598" DF="0" EFFECT_SIZE="1.065217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="1.224860207617706" LOG_CI_START="-1.1699837109238265" LOG_EFFECT_SIZE="0.027438248346939614" MODIFIED="2013-03-08 16:15:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9641778755569281" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="0.04491146846147558">
<NAME>incorrect diagnosis</NAME>
<DICH_DATA CI_END="16.7826372517289" CI_START="0.06761083337008598" EFFECT_SIZE="1.065217391304348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.224860207617706" LOG_CI_START="-1.1699837109238265" LOG_EFFECT_SIZE="0.027438248346939614" ORDER="16774" O_E="0.0" SE="1.4067431724198827" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="1.9789263531499557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.100636163997386" CI_START="0.19647737537300636" DF="0" EFFECT_SIZE="2.130434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.07.05" LOG_CI_END="1.363623940009433" LOG_CI_START="-0.7066874519875915" LOG_EFFECT_SIZE="0.3284682440109208" MODIFIED="2013-03-08 16:15:18 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.5339932712646607" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="0.6219218334161052">
<NAME>marked early remission</NAME>
<DICH_DATA CI_END="23.100636163997407" CI_START="0.19647737537300627" EFFECT_SIZE="2.130434782608696" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3636239400094334" LOG_CI_START="-0.7066874519875916" LOG_EFFECT_SIZE="0.3284682440109208" ORDER="16775" O_E="0.0" SE="1.2161111598657237" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="1.4789263531499557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="208.84778286640343" CI_START="0.6565381896012746" DF="0" EFFECT_SIZE="11.709677419354838" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.07.06" LOG_CI_END="2.3198298691438852" LOG_CI_START="-0.18274000674020552" LOG_EFFECT_SIZE="1.0685449312018398" MODIFIED="2013-03-08 16:15:18 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.09418423413261848" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.6737271563924447">
<NAME>serious complication of treatment</NAME>
<DICH_DATA CI_END="208.84778286640343" CI_START="0.6565381896012746" EFFECT_SIZE="11.709677419354838" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3198298691438852" LOG_CI_START="-0.18274000674020552" LOG_EFFECT_SIZE="1.0685449312018398" ORDER="16776" O_E="0.0" SE="1.4700219330149904" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.1609644835451287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.29633525231901" CI_START="0.12802943379190032" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.07.07" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-08 16:15:18 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.49481017826454565" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.68267825417953">
<NAME>severe extrapyramidal effects</NAME>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-07 10:55:34 +0000" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.34945412955719424" CI_START="0.03474824167369223" DF="0" EFFECT_SIZE="0.11019490254872563" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="29" I2="0.0" ID="CMP-001.07.08" LOG_CI_END="-0.4566098230301756" LOG_CI_START="-1.4590671666345325" LOG_EFFECT_SIZE="-0.9578384948323541" MODIFIED="2013-03-08 16:15:18 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="1.8006781312368878E-4" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="3.7454540382286834">
<NAME>treatment failure</NAME>
<DICH_DATA CI_END="0.34945412955719424" CI_START="0.03474824167369223" EFFECT_SIZE="0.11019490254872563" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="29" LOG_CI_END="-0.4566098230301756" LOG_CI_START="-1.4590671666345325" LOG_EFFECT_SIZE="-0.9578384948323541" ORDER="16777" O_E="0.0" SE="0.5888484058770802" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.3467424451039786" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="69.09028858730679" CI_START="0.1302643277951726" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2013-03-15 12:22:28 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.49243283298336993" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.6864445360982625">
<NAME>Leaving the study early: 3. Marked improvement/ hospital discharge</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluphenazine (oral)</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.09028858730679" CI_START="0.1302643277951726" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-13 15:35:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49243283298336993" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.6864445360982625">
<NAME>discharged due to marked improvement</NAME>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-08 16:15:15 +0000" MODIFIED_BY="[Empty name]" ORDER="1193" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.824621482963844" CI_END="4.035073362339115" CI_START="1.7264508639642901" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6393855142001628" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.6058514351099905" LOG_CI_START="0.23715422252744384" LOG_EFFECT_SIZE="0.42150282881871715" METHOD="MH" MODIFIED="2013-03-15 16:56:33 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6553730671405646" P_Q="0.6033698764396945" P_Z="7.417285139190806E-6" Q="6.392363546440405" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="642" TOTAL_2="683" WEIGHT="900.0" Z="4.481348573697054">
<NAME>Adverse effects: 1. Anticholinergic effects - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="102.66413118662545" CI_START="0.2698199527406068" DF="0" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="2.0114187362101177" LOG_CI_START="-0.568925938115776" LOG_EFFECT_SIZE="0.721246399047171" NO="1" P_CHI2="1.0" P_Z="0.27321853641437555" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="1.0956807283747563">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="102.66413118662554" CI_START="0.2698199527406067" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.011418736210118" LOG_CI_START="-0.5689259381157761" LOG_EFFECT_SIZE="0.721246399047171" ORDER="16778" O_E="0.0" SE="1.515707234611167" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.2973684210526315" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.153314549982804" CI_START="1.1857665596159404" DF="0" EFFECT_SIZE="2.2192028985507246" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.6183948235126538" LOG_CI_START="0.0739991984300508" LOG_EFFECT_SIZE="0.34619701097135236" NO="2" P_CHI2="1.0" P_Z="0.012674156918457273" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="2.4927962011315294">
<NAME>constipation</NAME>
<DICH_DATA CI_END="4.153314549982804" CI_START="1.1857665596159404" EFFECT_SIZE="2.2192028985507246" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.6183948235126538" LOG_CI_START="0.0739991984300508" LOG_EFFECT_SIZE="0.34619701097135236" ORDER="16779" O_E="0.0" SE="0.3197806849753264" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.10225968648328897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84387345476691" CI_START="0.13689962787560248" DF="0" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" NO="3" P_CHI2="1.0" P_Z="0.47268006447086963" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.7181252555316596">
<NAME>drooling</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="16780" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.4180209771949" CI_START="1.3927548431548842" DF="0" EFFECT_SIZE="3.621739130434783" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="0.9739596534320216" LOG_CI_START="0.14387467734636764" LOG_EFFECT_SIZE="0.5589171653891948" MODIFIED="2013-03-08 16:21:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.008305624461363946" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="99.99999999999999" Z="2.639386438891532">
<NAME>dryness mouth or throat</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-08 16:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="1195" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.4180209771949" CI_START="1.3927548431548842" EFFECT_SIZE="3.621739130434783" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.9739596534320216" LOG_CI_START="0.14387467734636764" LOG_EFFECT_SIZE="0.5589171653891948" ORDER="16781" O_E="0.0" SE="0.4875960239396137" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.23774988256172036" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2771567612128472" CI_END="2.722352945211165" CI_START="0.2967085912580396" DF="1" EFFECT_SIZE="0.8987466313042735" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="21.701076142731786" ID="CMP-001.09.05" LOG_CI_END="0.43494442954508916" LOG_CI_START="-0.5276698784154104" LOG_EFFECT_SIZE="-0.046362724435160645" MODIFIED="2013-03-15 16:56:33 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2584284623070857" P_Z="0.8502520481012763" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0" Z="0.18879684078371037">
<NAME>gastrointestinal distress and nausea</NAME>
<DICH_DATA CI_END="4.106565247465021" CI_START="0.010792798109624269" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6134787275380805" LOG_CI_START="-1.9668659467878138" LOG_EFFECT_SIZE="-0.6766936096248666" ORDER="16782" O_E="0.0" SE="1.515707234611167" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.2973684210526315" WEIGHT="38.6063224536938"/>
<DICH_DATA CI_END="4.8064139391982" CI_START="0.36887171271659114" EFFECT_SIZE="1.3315217391304348" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6818211704978929" LOG_CI_START="-0.4331246477879009" LOG_EFFECT_SIZE="0.124348261354996" MODIFIED="2013-03-15 16:56:33 +0000" MODIFIED_BY="[Empty name]" ORDER="16783" O_E="0.0" SE="0.6549246927318862" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.42892635314995564" WEIGHT="61.3936775463062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="309.14858771850186" CI_START="1.0593392602216287" DF="0" EFFECT_SIZE="18.096774193548388" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="2.4901672668547468" LOG_CI_START="0.02503506798903078" LOG_EFFECT_SIZE="1.2576011674218888" NO="6" P_CHI2="1.0" P_Z="0.045524729763688765" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.9997734776224858">
<NAME>increased salivation</NAME>
<DICH_DATA CI_END="309.14858771850186" CI_START="1.0593392602216287" EFFECT_SIZE="18.096774193548388" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4901672668547468" LOG_CI_START="0.02503506798903078" LOG_EFFECT_SIZE="1.2576011674218888" ORDER="16784" O_E="0.0" SE="1.448030856214907" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.0967933605504765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84387345476691" CI_START="0.13689962787560248" DF="0" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.09.07" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" MODIFIED="2013-03-08 16:25:41 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.47268006447086963" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.7181252555316596">
<NAME>nasal congestion</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" MODIFIED="2013-03-08 16:25:29 +0000" MODIFIED_BY="[Empty name]" ORDER="16789" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.174779111685815" CI_START="0.3384347165835682" DF="0" EFFECT_SIZE="3.1956521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.09.08" LOG_CI_END="1.4796440996168736" LOG_CI_START="-0.47052509348366944" LOG_EFFECT_SIZE="0.504559503066602" MODIFIED="2013-03-15 14:14:05 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.31049338189434905" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.0141873408385673">
<NAME>urinary disturbance</NAME>
<DICH_DATA CI_END="30.174779111685815" CI_START="0.3384347165835682" EFFECT_SIZE="3.1956521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4796440996168736" LOG_CI_START="-0.47052509348366944" LOG_EFFECT_SIZE="0.504559503066602" ORDER="16785" O_E="0.0" SE="1.1455390375204544" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="1.312259686483289" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.4098689206112" CI_START="0.2589333576919097" DF="0" EFFECT_SIZE="5.32258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.09.09" LOG_CI_END="2.0390564977236973" LOG_CI_START="-0.5868119969644302" LOG_EFFECT_SIZE="0.7261222503796336" MODIFIED="2013-03-15 14:14:05 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.27838077742179346" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.0839640004792295">
<NAME>vomiting</NAME>
<DICH_DATA CI_END="109.4098689206112" CI_START="0.2589333576919097" EFFECT_SIZE="5.32258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0390564977236973" LOG_CI_START="-0.5868119969644302" LOG_EFFECT_SIZE="0.7261222503796336" ORDER="16786" O_E="0.0" SE="1.542448152038488" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.379146301726947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07928482801851232" CI_END="6.145737282278008" CI_START="1.0434178920060977" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5323057161207454" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.7885739911146925" LOG_CI_START="0.018458279513916542" LOG_EFFECT_SIZE="0.40351613531430447" METHOD="MH" MODIFIED="2013-03-15 14:14:07 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9942017428398349" P_Q="0.9942201963088797" P_Z="0.03998367126412631" Q="0.07911382445175846" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="155" WEIGHT="400.0" Z="2.0539175619541563">
<NAME>Adverse effects: 2. Cardivascular effects - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.4866941615731655" CI_START="0.846639323879629" DF="0" EFFECT_SIZE="2.3434782608695652" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.8120234220442534" LOG_CI_START="-0.07230156370596168" LOG_EFFECT_SIZE="0.3698609291691458" NO="1" P_CHI2="1.0" P_Z="0.10111449195621572" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="99.99999999999999" Z="1.6394744288380967">
<NAME>dizziness, faintness, weakness</NAME>
<DICH_DATA CI_END="6.4866941615731655" CI_START="0.846639323879629" EFFECT_SIZE="2.3434782608695652" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.8120234220442534" LOG_CI_START="-0.07230156370596168" LOG_EFFECT_SIZE="0.3698609291691458" ORDER="16787" O_E="0.0" SE="0.5194568741089548" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.2698354440590465" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84387345476691" CI_START="0.13689962787560248" DF="0" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" NO="2" P_CHI2="1.0" P_Z="0.47268006447086963" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.7181252555316596">
<NAME>hypotension</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="16788" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84387345476691" CI_START="0.13689962787560248" DF="0" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" MODIFIED="2013-03-08 16:25:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.47268006447086963" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.7181252555316596">
<NAME>syncope</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="16790" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84387345476691" CI_START="0.13689962787560248" DF="0" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" MODIFIED="2013-03-15 14:14:07 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.47268006447086963" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.7181252555316596">
<NAME>tachycardia</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" MODIFIED="2013-03-15 14:13:52 +0000" MODIFIED_BY="[Empty name]" ORDER="16791" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.155425939323148" CI_END="2.971110956242854" CI_START="1.2621295949944853" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9364728420214086" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="27" I2="45.387576360323386" I2_Q="45.24583006249466" ID="CMP-001.11" LOG_CI_END="0.4729188708491732" LOG_CI_START="0.10110395039255364" LOG_EFFECT_SIZE="0.2870114106208634" METHOD="MH" MODIFIED="2013-03-15 12:22:28 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.10302307590838389" P_Q="0.10392409494549071" P_Z="0.002479178936788186" Q="9.131724589573434" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="330" TOTAL_2="351" WEIGHT="600.0" Z="3.025871190312068">
<NAME>Adverse effects: 3. CNS - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.719244714556494" CI_START="0.1658218413224946" DF="0" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.8273204583610819" LOG_CI_START="-0.7803582666620361" LOG_EFFECT_SIZE="0.0234810958495229" NO="1" P_CHI2="1.0" P_Z="0.9543437712856392" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.057252859624594525">
<NAME>anxiety, agitation, excitement and confusion</NAME>
<DICH_DATA CI_END="6.719244714556494" CI_START="0.1658218413224946" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8273204583610819" LOG_CI_START="-0.7803582666620361" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="16792" O_E="0.0" SE="0.9443584412166156" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.8918128654970761" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.601844822599888" CI_START="0.014637616985919968" DF="0" EFFECT_SIZE="0.3548387096774194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.9345916036102535" LOG_CI_START="-1.834529620962349" LOG_EFFECT_SIZE="-0.4499690086760476" NO="2" P_CHI2="1.0" P_Z="0.5241446342779452" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="0.6369696229534799">
<NAME>convulsion or seizures</NAME>
<DICH_DATA CI_END="8.601844822599888" CI_START="0.014637616985919968" EFFECT_SIZE="0.3548387096774194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9345916036102535" LOG_CI_START="-1.834529620962349" LOG_EFFECT_SIZE="-0.4499690086760476" ORDER="16793" O_E="0.0" SE="1.626595514685078" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.6458129683936136" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.093763717196325" CI_START="0.015211069763955837" DF="0" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="0.9081505217981177" LOG_CI_START="-1.817840241815138" LOG_EFFECT_SIZE="-0.4548448600085102" NO="3" P_CHI2="1.0" P_Z="0.5130737290994685" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.6540591083941909">
<NAME>depression</NAME>
<DICH_DATA CI_END="8.093763717196325" CI_START="0.015211069763955837" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9081505217981177" LOG_CI_START="-1.817840241815138" LOG_EFFECT_SIZE="-0.4548448600085102" ORDER="16794" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.708902970309269" CI_START="1.978913349466837" DF="0" EFFECT_SIZE="3.905797101449276" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="9" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="0.8869925793687952" LOG_CI_START="0.29642677820220925" LOG_EFFECT_SIZE="0.5917096787855023" NO="4" P_CHI2="1.0" P_Z="8.582609008395198E-5" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="99.99999999999999" Z="3.927520548709232">
<NAME>drowsiness</NAME>
<DICH_DATA CI_END="7.708902970309269" CI_START="1.978913349466837" EFFECT_SIZE="3.9057971014492754" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="9" LOG_CI_END="0.8869925793687952" LOG_CI_START="0.29642677820220925" LOG_EFFECT_SIZE="0.5917096787855022" ORDER="16795" O_E="0.0" SE="0.3469012749531155" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.12034049456409705" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.627970098047008" CI_START="0.5224460471648416" DF="0" EFFECT_SIZE="1.1717391304347826" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-001.11.05" LOG_CI_END="0.41962041936298544" LOG_CI_START="-0.2819585523526562" LOG_EFFECT_SIZE="0.06883093350516463" NO="5" P_CHI2="1.0" P_Z="0.7005496074785494" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="99.99999999999999" Z="0.3845786607956462">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.627970098047008" CI_START="0.5224460471648416" EFFECT_SIZE="1.1717391304347826" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.41962041936298544" LOG_CI_START="-0.2819585523526562" LOG_EFFECT_SIZE="0.06883093350516463" ORDER="16796" O_E="0.0" SE="0.4121109608576876" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.16983544405904655" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5998991697449005" CI_START="0.30950798295363163" DF="0" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.11.06" LOG_CI_END="0.5562903367015499" LOG_CI_START="-0.5093281450025042" LOG_EFFECT_SIZE="0.0234810958495229" NO="6" P_CHI2="1.0" P_Z="0.9311672694333402" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.08637632130591968">
<NAME>sedation and lethargy</NAME>
<DICH_DATA CI_END="3.5998991697449005" CI_START="0.30950798295363163" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5562903367015499" LOG_CI_START="-0.5093281450025042" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="16797" O_E="0.0" SE="0.6259495710495183" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.391812865497076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="55.717034333985644" CI_START="0.10160479258585489" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3793103448275863" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="1.7459879920544703" LOG_CI_START="-0.9930858063778718" LOG_EFFECT_SIZE="0.37645109283829925" METHOD="MH" MODIFIED="2013-03-15 12:22:28 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.5900631097061485" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="22" WEIGHT="100.0" Z="0.5387445817094044">
<NAME>Adverse effects: 4. Death - long term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="55.717034333985644" CI_START="0.10160479258585489" EFFECT_SIZE="2.3793103448275863" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7459879920544703" LOG_CI_START="-0.9930858063778718" LOG_EFFECT_SIZE="0.37645109283829925" ORDER="16798" O_E="0.0" SE="1.608945507833131" STUDY_ID="STD-Rifkin-1976" TOTAL_1="28" TOTAL_2="22" VAR="2.5887056471764116" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.047524289481023" CI_END="6.142630267512422" CI_START="0.7385108959027913" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.129882480809728" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="2.3210610846071384" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.7883543753860495" LOG_CI_START="-0.13164309277511968" LOG_EFFECT_SIZE="0.3283556413054649" METHOD="MH" MODIFIED="2013-03-15 12:22:28 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3592410164342116" P_Q="0.3753574104199634" P_Z="0.16179538105562818" Q="1.9597537182915532" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="276" TOTAL_2="294" WEIGHT="300.0" Z="1.3990587003800783">
<NAME>Adverse effects: 5. Endocrine - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.135309927981206" CI_START="0.27439009663084124" DF="0" EFFECT_SIZE="1.065217391304348" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.6165080640622012" LOG_CI_START="-0.5616315673683219" LOG_EFFECT_SIZE="0.027438248346939614" NO="1" P_CHI2="1.0" P_Z="0.9272597423629564" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="0.0912930473165883">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="4.135309927981206" CI_START="0.27439009663084124" EFFECT_SIZE="1.065217391304348" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6165080640622012" LOG_CI_START="-0.5616315673683219" LOG_EFFECT_SIZE="0.027438248346939614" ORDER="16799" O_E="0.0" SE="0.6920450513875203" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.47892635314995563" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="142.3187476031261" CI_START="0.3901561515589226" DF="0" EFFECT_SIZE="7.451612903225806" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="2.1532621133259764" LOG_CI_START="-0.4087615412102332" LOG_EFFECT_SIZE="0.8722502860578716" NO="2" P_CHI2="1.0" P_Z="0.18202244170685836" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.334553756481741">
<NAME>lactation</NAME>
<DICH_DATA CI_END="142.3187476031261" CI_START="0.3901561515589226" EFFECT_SIZE="7.451612903225806" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1532621133259764" LOG_CI_START="-0.4087615412102332" LOG_EFFECT_SIZE="0.8722502860578716" ORDER="16800" O_E="0.0" SE="1.5049453768961958" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.2648605874412326" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.4098689206112" CI_START="0.2589333576919097" DF="0" EFFECT_SIZE="5.32258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="2.0390564977236973" LOG_CI_START="-0.5868119969644302" LOG_EFFECT_SIZE="0.7261222503796336" NO="3" P_CHI2="1.0" P_Z="0.27838077742179346" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.0839640004792295">
<NAME>swelling of breasts</NAME>
<DICH_DATA CI_END="109.4098689206112" CI_START="0.2589333576919097" EFFECT_SIZE="5.32258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0390564977236973" LOG_CI_START="-0.5868119969644302" LOG_EFFECT_SIZE="0.7261222503796336" ORDER="16801" O_E="0.0" SE="1.542448152038488" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.379146301726947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.309468007009258" CI_END="2.8304359440410787" CI_START="1.6825230139690837" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="2.18226341567979" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="66" I2="60.40841100469028" I2_Q="69.15504268880792" ID="CMP-001.14" LOG_CI_END="0.45185333075769807" LOG_CI_START="0.22596101332479512" LOG_EFFECT_SIZE="0.3389071720412466" METHOD="MH" MODIFIED="2013-03-15 17:01:02 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0025078568328531503" P_Q="0.0010770433813693803" P_Z="4.0758814061801995E-9" Q="25.936168169366226" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="752" TOTAL_2="800" WEIGHT="900.0" Z="5.881084039083934">
<NAME>Adverse effects: 6a. Extrapyramidal effects - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84387345476691" CI_START="0.13689962787560248" DF="0" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" NO="1" P_CHI2="1.0" P_Z="0.47268006447086963" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.7181252555316596">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="16802" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3452701690829419" CI_END="9.563404525968116" CI_START="1.2268055259884574" DF="1" EFFECT_SIZE="3.4252645911988617" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.9806125265469028" LOG_CI_START="0.08877572353875654" LOG_EFFECT_SIZE="0.5346941250428296" MODIFIED="2013-03-15 16:59:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5568030537673034" P_Z="0.01876515763071535" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.00000000000001" Z="2.350163671860781">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="133.36649522003853" CI_START="0.4071009642960652" EFFECT_SIZE="7.368421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1250467383611165" LOG_CI_START="-0.3902978689102983" LOG_EFFECT_SIZE="0.8673744347254091" ORDER="16803" O_E="0.0" SE="1.4775258734678447" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.183082706766917" WEIGHT="11.171628396360711"/>
<DICH_DATA CI_END="8.874817419832507" CI_START="0.9669019969948097" EFFECT_SIZE="2.9293478260869565" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9481594271496795" LOG_CI_START="-0.014617542795275145" LOG_EFFECT_SIZE="0.4667709421772022" MODIFIED="2013-03-15 16:59:18 +0000" MODIFIED_BY="[Empty name]" ORDER="16804" O_E="0.0" SE="0.5655399579685298" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.31983544405904657" WEIGHT="88.8283716036393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="133.36649522003853" CI_START="0.4071009642960652" DF="0" EFFECT_SIZE="7.368421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="2.1250467383611165" LOG_CI_START="-0.3902978689102983" LOG_EFFECT_SIZE="0.8673744347254091" NO="3" P_CHI2="1.0" P_Z="0.17646443460223585" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="1.3517214685082324">
<NAME>associated movements</NAME>
<DICH_DATA CI_END="133.36649522003853" CI_START="0.4071009642960652" EFFECT_SIZE="7.368421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1250467383611165" LOG_CI_START="-0.3902978689102983" LOG_EFFECT_SIZE="0.8673744347254091" ORDER="16805" O_E="0.0" SE="1.4775258734678447" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.183082706766917" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="242.2454877234299" CI_START="0.7905612085313457" DF="0" EFFECT_SIZE="13.838709677419354" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-001.14.04" LOG_CI_END="2.3842556962488453" LOG_CI_START="-0.10206449954794235" LOG_EFFECT_SIZE="1.1410955983504516" NO="4" P_CHI2="1.0" P_Z="0.07201088614376315" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.7990492772933764">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="242.2454877234299" CI_START="0.7905612085313457" EFFECT_SIZE="13.838709677419354" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3842556962488453" LOG_CI_START="-0.10206449954794235" LOG_EFFECT_SIZE="1.1410955983504516" ORDER="16806" O_E="0.0" SE="1.4604767904944949" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.132992455573101" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.463845191578649" CI_START="1.0276863059858545" DF="0" EFFECT_SIZE="2.7695652173913046" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-001.14.05" LOG_CI_END="0.8729626230829802" LOG_CI_START="0.011860569552534924" LOG_EFFECT_SIZE="0.44241159631775756" NO="5" P_CHI2="1.0" P_Z="0.044014160218526284" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="99.99999999999999" Z="2.0139559337260837">
<NAME>facial rigidity</NAME>
<DICH_DATA CI_END="7.463845191578649" CI_START="1.0276863059858545" EFFECT_SIZE="2.7695652173913046" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8729626230829802" LOG_CI_START="0.011860569552534924" LOG_EFFECT_SIZE="0.44241159631775756" ORDER="16807" O_E="0.0" SE="0.5058156087676937" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.25584943007303257" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.980908123675935" CI_START="1.946949628002269" DF="0" EFFECT_SIZE="6.391304347826086" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" I2="0.0" ID="CMP-001.14.06" LOG_CI_END="1.3218242819779344" LOG_CI_START="0.28935471548323194" LOG_EFFECT_SIZE="0.8055894987305832" NO="6" P_CHI2="1.0" P_Z="0.002224159827193831" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="3.058543234734116">
<NAME>loss of associated movements</NAME>
<DICH_DATA CI_END="20.980908123675935" CI_START="1.946949628002269" EFFECT_SIZE="6.391304347826087" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="1.3218242819779344" LOG_CI_START="0.28935471548323194" LOG_EFFECT_SIZE="0.8055894987305832" ORDER="16808" O_E="0.0" SE="0.6064777341657684" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.36781524203884447" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0026281289050481067" CI_END="1.398480052532721" CI_START="0.6939018288726003" DF="1" EFFECT_SIZE="0.9850928210551051" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" I2="0.0" ID="CMP-001.14.07" LOG_CI_END="0.14565627611566148" LOG_CI_START="-0.15870196786606386" LOG_EFFECT_SIZE="-0.00652284587520118" MODIFIED="2013-03-08 16:05:50 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.959114153292736" P_Z="0.9330486118872734" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="99.99999999999999" Z="0.08400983541531792">
<NAME>restlessness, insomnia</NAME>
<DICH_DATA CI_END="15.640507378231115" CI_START="0.07123794029949233" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="16809" O_E="0.0" SE="1.3754318832632446" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="1.891812865497076" WEIGHT="2.5114557631300665"/>
<DICH_DATA CI_END="1.3988227614154103" CI_START="0.6911775026440103" EFFECT_SIZE="0.9832775919732442" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.14576269046354953" LOG_CI_START="-0.16041040628809425" LOG_EFFECT_SIZE="-0.007323857912272349" ORDER="16810" O_E="0.0" SE="0.1798475926131875" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.032345156568759054" WEIGHT="97.48854423686991"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9844403710809172" CI_END="7.138882433490416" CI_START="1.7600604589420359" DF="1" EFFECT_SIZE="3.5446952890512855" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="9" I2="0.0" ID="CMP-001.14.08" LOG_CI_END="0.8536302298495041" LOG_CI_START="0.24552758629933877" LOG_EFFECT_SIZE="0.5495789080744214" MODIFIED="2013-03-15 17:00:46 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3211052302888129" P_Z="3.9609125974811587E-4" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0" Z="3.542674507054188">
<NAME>rigidity</NAME>
<DICH_DATA CI_END="60.93942728916375" CI_START="1.1701560901933319" EFFECT_SIZE="8.444444444444445" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7848983683913369" LOG_CI_START="0.0682437972915963" LOG_EFFECT_SIZE="0.9265710828414665" ORDER="16811" O_E="0.0" SE="1.0083713926411617" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="1.016812865497076" WEIGHT="11.15751011353256"/>
<DICH_DATA CI_END="6.2482565123882" CI_START="1.3733556983755342" EFFECT_SIZE="2.9293478260869565" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7957588505152087" LOG_CI_START="0.13778303383919563" LOG_EFFECT_SIZE="0.4667709421772022" MODIFIED="2013-03-15 17:00:46 +0000" MODIFIED_BY="[Empty name]" ORDER="16812" O_E="0.0" SE="0.3864982517483114" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.1493808986045011" WEIGHT="88.84248988646743"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.151031888090999" CI_END="8.108128520050125" CI_START="1.2532744244916563" DF="1" EFFECT_SIZE="3.18774373259053" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" I2="13.121433876300976" ID="CMP-001.14.09" LOG_CI_END="0.9089206239758577" LOG_CI_START="0.09804617713395422" LOG_EFFECT_SIZE="0.5034834005549059" MODIFIED="2013-03-15 17:01:02 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.28333328927614454" P_Z="0.014935525932298452" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0" Z="2.433938659048084">
<NAME>tremor</NAME>
<DICH_DATA CI_END="195.45615269511896" CI_START="0.6859442402398874" EFFECT_SIZE="11.578947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2910493459858756" LOG_CI_START="-0.16371118624712108" LOG_EFFECT_SIZE="1.0636690798693773" ORDER="16813" O_E="0.0" SE="1.4419384878942698" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.0791866028708132" WEIGHT="9.141554824006077"/>
<DICH_DATA CI_END="6.4866941615731655" CI_START="0.846639323879629" EFFECT_SIZE="2.3434782608695652" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.8120234220442534" LOG_CI_START="-0.07230156370596168" LOG_EFFECT_SIZE="0.3698609291691458" MODIFIED="2013-03-15 17:01:02 +0000" MODIFIED_BY="[Empty name]" ORDER="16814" O_E="0.0" SE="0.5194568741089548" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.2698354440590465" WEIGHT="90.85844517599392"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.13170247821856" CI_END="2.100008159704597" CI_START="1.1831529519164392" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.576271186440678" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="29" I2="87.5682206727527" I2_Q="60.24762935612578" ID="CMP-001.15" LOG_CI_END="0.322220982213822" LOG_CI_START="0.07304089160975992" LOG_EFFECT_SIZE="0.19763093691179093" METHOD="MH" MODIFIED="2013-03-15 12:22:28 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="2.3447425426592616E-5" P_Q="0.05637014380127747" P_Z="0.001877264725774041" Q="7.546719733713027" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" WEIGHT="400.0" Z="3.1089925173315858">
<NAME>Adverse effects: 6b. Extrapyramidal effects - medium term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.427088257278379" CI_START="0.4201817671143303" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.534925288893081" LOG_CI_START="-0.3765627967978314" LOG_EFFECT_SIZE="0.07918124604762482" NO="1" P_CHI2="1.0" P_Z="0.7334609514768202" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.34052532982197475">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="3.42708825727838" CI_START="0.4201817671143302" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5349252888930811" LOG_CI_START="-0.3765627967978315" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="16815" O_E="0.0" SE="0.5354126134736338" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.28666666666666674" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="188.94601143053802" CI_START="0.6403945713587241" DF="0" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="2.276337728579093" LOG_CI_START="-0.19355235826264286" LOG_EFFECT_SIZE="1.0413926851582251" NO="2" P_CHI2="1.0" P_Z="0.09837569735812605" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.6527797472020616">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="188.94601143053802" CI_START="0.6403945713587241" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.276337728579093" LOG_CI_START="-0.19355235826264286" LOG_EFFECT_SIZE="1.0413926851582251" ORDER="16816" O_E="0.0" SE="1.4508256631639465" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="2.104895104895105" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2871202981966547" CI_START="0.9246087147374551" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.10961913929089225" LOG_CI_START="-0.03404201751209278" LOG_EFFECT_SIZE="0.037788560889399754" NO="3" P_CHI2="1.0" P_Z="0.3024958420916226" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.00000000000001" Z="1.03109594853664">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="1.2871202981966547" CI_START="0.9246087147374551" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.10961913929089225" LOG_CI_START="-0.03404201751209278" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="16817" O_E="0.0" SE="0.08438727464026863" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.0071212121212121254" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.324601752091695" CI_START="1.3550073741927213" DF="0" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="1.3487837202633082" LOG_CI_START="0.1319416587251794" LOG_EFFECT_SIZE="0.7403626894942439" NO="4" P_CHI2="1.0" P_Z="0.017079117650459563" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="2.385000079750219">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="22.324601752091695" CI_START="1.3550073741927213" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3487837202633082" LOG_CI_START="0.1319416587251794" LOG_EFFECT_SIZE="0.7403626894942439" ORDER="16818" O_E="0.0" SE="0.7147790504128467" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.5109090909090909" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.92444769330829" CI_END="2.7243489434550767" CI_START="0.4151934869689188" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.063546866646319" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.4352627326502498" LOG_CI_START="-0.3817494677695322" LOG_EFFECT_SIZE="0.026756632440358783" METHOD="MH" MODIFIED="2013-03-15 17:01:32 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.5705475237613569" P_Q="0.636562618441922" P_Z="0.8978520880469689" Q="1.7016702255588494" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="386" TOTAL_2="411" WEIGHT="400.0" Z="0.1283751598904753">
<NAME>Adverse effects: 7. Others - short term</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.601844822599888" CI_START="0.014637616985919968" DF="0" EFFECT_SIZE="0.3548387096774194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.9345916036102535" LOG_CI_START="-1.834529620962349" LOG_EFFECT_SIZE="-0.4499690086760476" NO="1" P_CHI2="1.0" P_Z="0.5241446342779452" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="0.6369696229534799">
<NAME>convulsion or seizures</NAME>
<DICH_DATA CI_END="8.601844822599888" CI_START="0.014637616985919968" EFFECT_SIZE="0.3548387096774194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9345916036102535" LOG_CI_START="-1.834529620962349" LOG_EFFECT_SIZE="-0.4499690086760476" ORDER="16819" O_E="0.0" SE="1.626595514685078" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.6458129683936136" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.4098689206112" CI_START="0.2589333576919097" DF="0" EFFECT_SIZE="5.32258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="2.0390564977236973" LOG_CI_START="-0.5868119969644302" LOG_EFFECT_SIZE="0.7261222503796336" NO="2" P_CHI2="1.0" P_Z="0.27838077742179346" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.0839640004792295">
<NAME>diarrhoea</NAME>
<DICH_DATA CI_END="109.4098689206112" CI_START="0.2589333576919097" EFFECT_SIZE="5.32258064516129" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0390564977236973" LOG_CI_START="-0.5868119969644302" LOG_EFFECT_SIZE="0.7261222503796336" ORDER="16820" O_E="0.0" SE="1.542448152038488" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="2.379146301726947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.14480006819675" CI_START="0.2205504734287853" DF="0" EFFECT_SIZE="1.065217391304348" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.16.03" LOG_CI_END="0.7113685023314895" LOG_CI_START="-0.6564920056376103" LOG_EFFECT_SIZE="0.027438248346939614" NO="3" P_CHI2="1.0" P_Z="0.9373262937037465" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="0.07863079348450956">
<NAME>intercurrent infection</NAME>
<DICH_DATA CI_END="5.144800068196749" CI_START="0.22055047342878534" EFFECT_SIZE="1.065217391304348" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7113685023314894" LOG_CI_START="-0.6564920056376102" LOG_EFFECT_SIZE="0.027438248346939614" ORDER="16821" O_E="0.0" SE="0.8034880333997652" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="0.6455930198166222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2324016388019154" CI_END="3.7752465896679426" CI_START="0.15202309776887513" DF="1" EFFECT_SIZE="0.7575781685098258" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="18.85762169448636" ID="CMP-001.16.04" LOG_CI_END="0.5769453239213653" LOG_CI_START="-0.8180904221113077" LOG_EFFECT_SIZE="-0.12057254909497116" MODIFIED="2013-03-15 17:01:32 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.26694056339417516" P_Z="0.7347616997352129" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="117" WEIGHT="100.0" Z="0.3387982772805539">
<NAME>rash</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="16822" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="14.36072877715013"/>
<DICH_DATA CI_END="3.3527532346317575" CI_START="0.037603857398174234" EFFECT_SIZE="0.35507246376811596" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5254015901775487" LOG_CI_START="-1.4247676029229945" LOG_EFFECT_SIZE="-0.44968300637272285" MODIFIED="2013-03-15 17:01:32 +0000" MODIFIED_BY="[Empty name]" ORDER="16823" O_E="0.0" SE="1.1455390375204544" STUDY_ID="STD-Goldberg-1964" TOTAL_1="92" TOTAL_2="98" VAR="1.312259686483289" WEIGHT="85.63927122284987"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8056177331654535" CI_END="1.2473462868256964" CI_START="0.5091360147299722" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7969121140142518" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.09598703854671556" LOG_CI_START="-0.2931661812080304" LOG_EFFECT_SIZE="-0.09858957133065743" METHOD="MH" MODIFIED="2013-03-15 17:05:08 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.3694191038768837" P_Q="0.37753863984799485" P_Z="0.3206663014147101" Q="0.7787013844150577" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="44" WEIGHT="200.0" Z="0.9930896071275518">
<NAME>Sensitivity analysis: 1. CHRONIC versus ACUTE</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4179145657902805" CI_START="0.242530921895333" DF="0" EFFECT_SIZE="0.5864197530864198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.15165006390513366" LOG_CI_START="-0.6152328824127" LOG_EFFECT_SIZE="-0.23179140925378314" MODIFIED="2013-03-15 17:04:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.23609515447159535" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="1.1848035381267015">
<NAME>Acute: Global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.4179145657902803" CI_START="0.24253092189533307" EFFECT_SIZE="0.5864197530864198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.15165006390513358" LOG_CI_START="-0.6152328824126999" LOG_EFFECT_SIZE="-0.23179140925378314" MODIFIED="2013-03-15 17:04:59 +0000" MODIFIED_BY="[Empty name]" ORDER="16758" O_E="0.0" SE="0.4504708387989029" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.20292397660818712" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.550082129088543" CI_START="0.5562575567955155" DF="0" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2013-03-15 17:05:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7768249154530719" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.28345911931358597">
<NAME>Chronic: global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.550082129088543" CI_START="0.5562575567955155" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2013-03-15 17:05:08 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.26144148169647513" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.06835164835164834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8079526174273596" CI_END="1.1160598158245412" CI_START="0.567314016034943" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7957112392386068" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.047687471471069234" LOG_CI_START="-0.24617648664252567" LOG_EFFECT_SIZE="-0.09924450758572823" METHOD="MH" MODIFIED="2013-07-01 17:51:53 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.6676601837028486" P_Q="0.9904801734119257" P_Z="0.18555340910466434" Q="1.4236346901193617E-4" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="64" WEIGHT="200.0" Z="1.3238483669797185">
<NAME>Sensitivity analysis: 2. LOW DOSES (1-5 mg/day) versus HIGH DOSES (5mg/day&gt;)</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.923700879431225E-31" CI_END="1.3124918683512852" CI_START="0.4799127502814731" DF="0" EFFECT_SIZE="0.7936507936507935" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="100.0" ID="CMP-001.18.01" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756298" MODIFIED="2013-03-18 11:41:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.36787135221972267" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0" Z="0.900467821745938">
<NAME>High dose: Global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.3124918683512852" CI_START="0.4799127502814732" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756292" MODIFIED="2013-03-18 11:36:48 +0000" MODIFIED_BY="[Empty name]" ORDER="16828" O_E="0.0" SE="0.2566573900611784" STUDY_ID="STD-Carpenter-1999" TOTAL_1="18" TOTAL_2="20" VAR="0.06587301587301587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8056177331654535" CI_END="1.2473462868256964" CI_START="0.5091360147299722" DF="1" EFFECT_SIZE="0.7969121140142518" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.09598703854671556" LOG_CI_START="-0.2931661812080304" LOG_EFFECT_SIZE="-0.09858957133065743" MODIFIED="2013-03-18 11:41:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3694191038768837" P_Z="0.3206663014147101" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="0.9930896071275518">
<NAME>Flexible dose: Global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.4179145657902803" CI_START="0.24253092189533307" EFFECT_SIZE="0.5864197530864198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.15165006390513358" LOG_CI_START="-0.6152328824126999" LOG_EFFECT_SIZE="-0.23179140925378314" MODIFIED="2013-03-18 11:40:47 +0000" MODIFIED_BY="[Empty name]" ORDER="16829" O_E="0.0" SE="0.4504708387989029" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.20292397660818712" WEIGHT="38.479809976247026"/>
<DICH_DATA CI_END="1.550082129088543" CI_START="0.5562575567955155" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2013-03-18 11:41:33 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.26144148169647513" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.06835164835164834" WEIGHT="61.52019002375297"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8079526174273596" CI_END="1.1160598158245412" CI_START="0.567314016034943" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7957112392386068" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.047687471471069234" LOG_CI_START="-0.24617648664252567" LOG_EFFECT_SIZE="-0.09924450758572823" METHOD="MH" MODIFIED="2013-03-18 13:55:14 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.6676601837028486" P_Q="0.9904801734119257" P_Z="0.18555340910466434" Q="1.4236346901193617E-4" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="64" WEIGHT="200.0" Z="1.3238483669797185">
<NAME>Sensitivity analysis: 3. OPERATIONAL CRITERIA versus LOOSE DEFINITIONS</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.923700879431225E-31" CI_END="1.3124918683512852" CI_START="0.4799127502814731" DF="0" EFFECT_SIZE="0.7936507936507935" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="100.0" ID="CMP-001.19.01" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756298" MODIFIED="2013-03-18 12:08:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.36787135221972267" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0" Z="0.900467821745938">
<NAME>DSM-III-R: Global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.3124918683512852" CI_START="0.4799127502814732" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756292" MODIFIED="2013-03-18 12:08:19 +0000" MODIFIED_BY="[Empty name]" ORDER="16828" O_E="0.0" SE="0.2566573900611784" STUDY_ID="STD-Carpenter-1999" TOTAL_1="18" TOTAL_2="20" VAR="0.06587301587301587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8056177331654535" CI_END="1.2473462868256964" CI_START="0.5091360147299722" DF="1" EFFECT_SIZE="0.7969121140142518" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.09598703854671556" LOG_CI_START="-0.2931661812080304" LOG_EFFECT_SIZE="-0.09858957133065743" MODIFIED="2013-03-18 12:08:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3694191038768837" P_Z="0.3206663014147101" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="0.9930896071275518">
<NAME>Loose definition: global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.4179145657902803" CI_START="0.24253092189533307" EFFECT_SIZE="0.5864197530864198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.15165006390513358" LOG_CI_START="-0.6152328824126999" LOG_EFFECT_SIZE="-0.23179140925378314" MODIFIED="2013-03-18 12:08:12 +0000" MODIFIED_BY="[Empty name]" ORDER="16758" O_E="0.0" SE="0.4504708387989029" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.20292397660818712" WEIGHT="38.479809976247026"/>
<DICH_DATA CI_END="1.550082129088543" CI_START="0.5562575567955155" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2013-03-18 11:50:28 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.26144148169647513" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.06835164835164834" WEIGHT="61.52019002375297"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8079526174273596" CI_END="1.1160598158245412" CI_START="0.567314016034943" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7957112392386068" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.047687471471069234" LOG_CI_START="-0.24617648664252567" LOG_EFFECT_SIZE="-0.09924450758572823" METHOD="MH" MODIFIED="2013-03-18 13:55:17 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.6676601837028486" P_Q="0.9904801734119257" P_Z="0.18555340910466434" Q="1.4236346901193617E-4" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="64" WEIGHT="200.0" Z="1.3238483669797185">
<NAME>Sensitivity analysis: 4. BEFORE 1990 versus AFTER 1990</NAME>
<GROUP_LABEL_1>Fluphenazine (oral)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluphenazine (oral)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8056177331654535" CI_END="1.2473462868256964" CI_START="0.5091360147299722" DF="1" EFFECT_SIZE="0.7969121140142518" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.09598703854671556" LOG_CI_START="-0.2931661812080304" LOG_EFFECT_SIZE="-0.09858957133065743" MODIFIED="2013-03-18 11:33:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3694191038768837" P_Z="0.3206663014147101" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="0.9930896071275518">
<NAME>Before 1990: Global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.4179145657902803" CI_START="0.24253092189533307" EFFECT_SIZE="0.5864197530864198" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.15165006390513358" LOG_CI_START="-0.6152328824126999" LOG_EFFECT_SIZE="-0.23179140925378314" MODIFIED="2013-03-18 11:18:21 +0000" MODIFIED_BY="[Empty name]" ORDER="16829" O_E="0.0" SE="0.4504708387989029" STUDY_ID="STD-Clark-1971" TOTAL_1="18" TOTAL_2="19" VAR="0.20292397660818712" WEIGHT="38.479809976247026"/>
<DICH_DATA CI_END="1.550082129088543" CI_START="0.5562575567955155" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2013-03-18 11:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.26144148169647513" STUDY_ID="STD-Hordern-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.06835164835164834" WEIGHT="61.52019002375297"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.923700879431225E-31" CI_END="1.3124918683512852" CI_START="0.4799127502814731" DF="0" EFFECT_SIZE="0.7936507936507935" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="100.0" ID="CMP-001.20.02" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756298" MODIFIED="2013-03-18 11:33:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.36787135221972267" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0" Z="0.900467821745938">
<NAME>After 1990: Global state - not improved - short term</NAME>
<DICH_DATA CI_END="1.3124918683512852" CI_START="0.4799127502814732" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.11809662138000931" LOG_CI_START="-0.31883771161513524" LOG_EFFECT_SIZE="-0.10037054511756292" MODIFIED="2013-03-18 11:18:06 +0000" MODIFIED_BY="[Empty name]" ORDER="16828" O_E="0.0" SE="0.2566573900611784" STUDY_ID="STD-Carpenter-1999" TOTAL_1="18" TOTAL_2="20" VAR="0.06587301587301587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-07-09 13:58:47 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-08 17:17:19 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: 2006 search.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAJRCAYAAABvFjF9AAA6x0lEQVR42u2dD4RV2/v/L0mSJJIr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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-07-08 17:16:38 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: 2012 update search (no additional studies).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZEAAAEkCAYAAADuJgyRAAAaR0lEQVR42u3dX6RV6/rA8U2SJNkk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-07-09 13:58:47 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAXHklEQVR42u1dW2wc13n+Ke7cuLzNLBmbdiBIIuEXxUAqQ5aomI6x
klMTdqskSFADbRFLDzSEyC6KvNgFekkfKsGAH5w4QSUUVds4QY0KKqTUlmrJa1hLtTDVCihip4VB
iqpcc+mQnCElkrszs+T2XGbntrPL5XJJLqX/42Vmzpxz/rNnvznnn9nz7Q+AQFRGE6jYCYhKMLZh
HyBWAHIEgRxBIEcQyBEEcgSBHEEgRxD3OmLYBREwsAt8z1aRI+s9vDbgSL1URZ4CzjUI9EcQyBEE
cgSBHEEgR+oGfcMLIipxJEkgKiNR+ZKb1cCHy9jW4iu08KHogsno3K1Z5EJ140gqlZoUv95QDewn
rYoaJb7z2QoFD0QXLL7S0PFtFcedqucabXwJoEsRZZVcbJ2ymAaw4yJ96Ga3SC2kI5OnxINaWpL4
hadJokz29BYprrMsZ5L8IiV/dqsYt8lex6BIstiD4hk3jVU3pJJMI3GxZYSb0tx6kp0SaYNA2pBk
PzDi2O4s2t3VrlHbimcb3Lq6qT2nIGm7rw0U3QqzR17ki5JEXldWFAbToB3fhWSo2h/pI0kLutWy
SPYLE+8fBEiIk/Q9UCVT3k62Q5P/Yj6Xme1guRdarBby3m6fMy+R/k7ImZe8mhKGJSXozs/fbyfF
f9BxjKWJCX5WOElr3fuZNXOIbJcnWhfceuBshrTBJm1I8Ss+6dheLtrNH2a2Fc82resDa2Yvedf/
faGzWDAhWOdjbhsozM9b9rKd+T8wZ4nJjnftc08DHLaRDFVxhPoj5lXSywroXyPH49rAE6RXx7Tr
9G0Zg9E82V7XlH3jmvIEKxGztVFygeYFGFBIzlHN91GHKYBu8loGAKw9UzmWZpj87DjLK2ugWGR7
S6MWnXpgj+a2gVOC2LZZLseutTtsm9b1OChkz74pmG4bbsIe2W0DxYw2LbOd3ADQymIHs1nSsN3I
kXIIrItPpiD99l/SIX/nUv5Aih7TP8lkG3okWsVE9kdyfjn/wj9Psdll2KKniznphiSKl9yjVNFX
HKaccPOS3bTtLzLMbXhtKLUN8Mwlanvpe57tYF3gK0ja7xWk/4dO043d/cNX+lO0lkLHFG9PEQZ+
XlNQy3bGwGPb2c2EeDVwG0lnhWtkM1DivixO/tMdco54u6SPm3QY8e48h0niJTfnMPMZhnlGcPM2
kQTvEr7mng62ocR2aoTazvhse3UN+9xPsq8XAi3uBv0f2E57of0OewWZU2Q7guNF1Sw/AmQcWf6f
0UNekrSLDTaCAn0fhbMrWa2JnrPhDBnlpV6g5YbT+g469NtwpcXNKd6wZZam8jRpJxwaBrgyApri
ZnLqoSBt2OtS67WwbfFRYlsr2s7y2cOpS9xlS4Q6jHlmH9wwAy3OwiPce12aPkw9I1LL84RFj4pI
hqpHQmWfDi1He3wnZmzmeqYSYrbkbvI9TViYJec6xGN3aE6RlptL9jTTcp3C695TDOX1VoOl7edp
M3mJ5jWekrJ3vOGB10MRP9pDmSk+yO6AE2IuYFt4gNjOCgukrlSnqN7loyKvy8i1XiF+RitzZEzh
cD74+gaz3Gc61dZDKfbePrGDZH0AV0lU5Y/UBclU1VmvPrNY81PUnoxW18e5gfrQH/H7I/XniN/3
q9iIQ2lhVqjZzJmX5uvZ6vibRwA5slEcuReAaxV9axUNnIUr9g8CcG0AAjmCQI4gkCOIzQf6rHhf
s5LfjhzBSycSeZxrEOiPIJAjCOQIAjmCuO85so5CBH3zm3CfoRmUmm6eD8zmAJLj9DcKb+TLnakK
lcr+iN+VqTGrcpkfRTfBSQufKmg531EOh9dlZa2dYX/0hxXPVxZArQn9fJTYb6ycbxUarPx+HHfq
O9fo1md/7fapHRdbbbKRJQ2gSxaHXOWU3SpwAZQspHlWlkdvERXdlV05aXGRiqwyiihf4Re6Kkpa
F5NcOed4/iSXYfZeEyArinKXK7NiLWH2bEVymxC0xdvA2uTaSgu0FuFaL5KhrhzpMzXB7dOEaMUS
AJ1K2yLA/GWr31VOJWK2SJ9YFiZSB1lWnkeVLIUJqpjsykmbtf5VBTiqW8qzDg8nZ3MWk1zRczuK
+Z2qLRGgo9VqnSdWZi3pVd6SWbbyVpXa9hfzBW2xlIlLXARGbT1H2NJmXb4LIJpIhrpyxNLgvCt4
MMfgpkllUtM5Jmw64iqnnr8JYy8CVU4NcOUUzyO7giomu2JpChdSXVTAcIobmrKfS67oOU+m5cwN
nwIIf57+lMu69B9ze2TvearBmr5YzBe0RXFbG3ie7VBbB+jayvRu0vxPl5AMZVDTWkX9QfLODU9q
Jfoo8v505wfMVCUBFIQEVZ42K22DvuOF067wyi/M8sm0WH6Bzimd9sB/TYc0WNfMEg1WQLzltcmx
RWppapsOabDw85p8eQ1WdVONkEqlxD7naNiVaBF0FC7+rZvvmh66A+V5aHJTOI3Lpx7e9tbdEnPX
AjItZ/wjpYSFyVfn/bIumtEs1ug1oSnobhfb5NgitSikllAuxBrnmhmqVxKOOkcv98EuGSDW103+
56d3v+6+8bk+6PXfUjp5qJhLCKXluPhqWRgtvYRznjCLjihMURf7hMwjWU1a9ku9pAwTeMV6uwaL
+YK2KNrhE4nf3XFbclrLkHnmExw66sqRF8fIv7E3nevxhCnYMwCzi3fJ+zPX1vM3JO21HjZemaIV
GEh4ntsJMXc7lGZ0SFR8FZ9/pVQ2Y3jCLEoE5tqIHwO0qeLB95ms63e4rGu8T8yRps1+9+65Yr7b
Cclni+LO8Wdm2I5jq/VtkWo6P0adXl39kQaA/vsXhHrWZ//uzzX0R6L9kS2rr1Hr60AUEv4BDzni
58iW7Qyjvj5mU9C5zuMM4/MisQuiBinsgjU/Q0MgRxAI5AgCOYJAn3Wdb5qwC1CDdc8Or3VrOGqw
EOiPIJAjCOQIAjmCQI5sAvQVjhH14AiNOiF3s7WlwTBRyTKxqM60RiRmxUItDSkTn6pi5sDew6E8
D68qDlb8DHKhqnEklZpU+HLSEvVSZCyqY1GpHa1r+dS+duVWf+nxKjRYnx3DcafKuUYzlt2RQ+WR
qaigiSdwKZUdlzr5VdgrPg7JLBNAFaNZqXLyia/SyFRO1CoqpZKdqFndikjVVk69XHrllKPobmFl
3HxOlCuCNIuI5dl31VR8j9dBFVdORCxSwRkvDlZIBlbGjiZiHKxq/RFfDAguW3pbyRSVJ4WJOzQq
lpA5wY+tL8i/05M0rtXeWR7NCiao9mm7ZMo/IwcXMgB/NWnkzMxsJ8Dvxa34glvvT5Vbi75yAL/5
v5btbMfJN99i6fx58DdYRKyi/Zg4ydejQuLiJH0ayOugdt+eM6dp9LNfdhxzZWDnbR53i5WtYOcL
jHFUFUeIQ/LV19yjcSZbOjuqOW+JE4TKvKk95lzHv6JDujZGZVUCKFToNsYu8X1jMHqBbL9Cjh7T
lP17NIXU9OZ0MbgW3VwY6/GVI8hr0/vYjpNPsFl8KvCicnH7Mo/KRWB+RbsF/jr+mOwdKkbc4sjt
Ado+cAN3lbPzK+RIOfjXs1J5Uvcd06deIn9eaKtgVCwAd49KmiAskwpFzGJxp+zl/lSk9Ar8wiwn
38hTSzDP1jXrO2eVA+Xte7Z9UbQqxsGKtCP5xJwGfl5TQYM1Fb4p2RbWUYGbUNDdo6BMqlT4xJzZ
wrTvPiggvaLoKpZx8j2+mGn5Pr9DaUpcjbIPPJKWV4cTEWs4pMEKvqQydvQCDhhV8k5tDt/K9sKO
QAKNijXM9gSq1NsBvRKTSfk8mddKhE+MmdNZ36Ua680MBspl4ZGcPx+NsPV33DH670BUrhvFBpE9
mu7UQdjwGt8Tb1BVlyMD+xh65eALirajoL6mSn9EzH0YynDdks4FEmZs8TTfY0q9ZtGaYRKqrDdI
lEStYphr+67P2gfZHR8FyrUMLl7354t/W1iY488ujj7oj8p1WHrD2fumRBlN6li8Q0j3IPR3iosf
0ohbdwx2TIkwyNrnQxk7f4qrJKrxR6qGarHvadAfmtCSqXujH+y2iXWKg7X1/ZHVc6TVLsTiU/xG
2VyoNupVo6N1yv+dX8iRe0Knt67AtYoYB6vq/kEArg1AIEcQyBEEcgSx+UCfFe9rVvLbkSNrGF63
aAjwqlDAuQaB/ggCOYJAjiCQIwjkSAh6TadWW0T3n0ItRL1Qy+e+Va8Z8TI6KogosCXvq6tNDnzB
uGrPe+mOIZKX1BvVUCctfKpVDHw/K977FtYYU2D16C9/av/qazsQGDy8iFgHXEMpVu8qNFhGFsed
Ol8Kyc4hkVyx9nHpKriSK3VI0tIsPZmVFN7n+htiXOcCqTjLBV5+Wg/7yShUozUTH2JyqSvSUDYt
D7EUMc4XGtrxIcrrLkVyomx1H2cCKuARsdx0Vl/nkFMvj4PF5WCsXawqmdaZpJUNUXlZVhSPp0FY
xDhY9R4ul0/O0QhVb7WdANgumxKVNeknZ3PPsnSQMz/lY5Xab02rTBClzpo/2cHSivmdCzoFJ6T2
TgBNOM2iZn070689N9FPqjkxa0lc7xUTT9JRdP49s5+Hwrr7j1acTzHWO750prxqOunUS239xGK2
eHtZVROXdrKdvfrpOJnnOuLWY08DdFtIhjpzhOuheMQpexTGqHjBi1wFee0wX/snPw4K31MEOMLf
h2J+F6duTpkAL96EMRo1ZEY70j+uHSHV/NiNcPXiGJNb0ShbXEqVmwbdia21259OMeZbmWof5rZu
uRqs69oAX55/kUu7xL9IHyb+zaf49d919lmDQqoSyRXdCCFZVJTcyieUgrBcyisMrtzK7s7nuRrL
7rafNL2IWG56oG3l4mDxhJGnl/JOHKxbPbwe9Fnr77NGxbVybjx1XvO1QJAqG4L5HT9x2K3me4Fa
+tzCjvCqvTDlxOXtKExfcN4o3Z8e0cJQ27pBf4HtfL3pXScO1jtk8tHxSdH6XAo84pRwHnpDkqsd
0MeDTeVGmCxq2PZFs3LyD2v6Dk4Qsbdb4lGzTgVqabdBHWR70i4mvFqazrIoWzbkL2cTThsUf/rw
SLEwJ15p2xZAaeeXnCDTKpxoWufxE/D14chslkacuv190QzGmoJzknmLD1RPiVQgJbQWI12Bm791
oYe+L+IDYOS+dYVFzbKDTsGJTiH3H2xvJi/RvO/zKFuktrknexxpGFWEeemi65aQermtUBysObnr
T9hOfH6ASricaFovoE6vnv5IHZ+y1QH1iYhVkwbrPvFH1ocj0kYGVNZm6hDuqKD5154hR/wcWZ9Z
eENjbtclaFpTcHnicnUPie6PuQY9tSigBqvBh0sEcgSBHEEgRxD3GdBnjQJqsFCD1WiXzlLj9QBq
sBDojyCQIwjkCAI5gkCOlIW+ASXWVg4RRt3XBtgdSwV5xl3REV5JomRXu7hEzkWXUFf4vLdMuXIa
rOD3s+K973pqsNqlzCQkyp7uX3WoqwNlgnDl8jWVcxA+dVvFcWfD5prlMU27k/NHuHKiU9mDbnSq
QZscFdPpRd0pu5G0zogtdKG7G0nL0VKRLDwql+wE4TovCDWVA1th+QG6ZIlrsITBNGjHMQ7WhnFE
2KnaYAHs/cCa2ctSts+Zl8h7EfuBG53q2pfgS/9WTKfITLj5X5q8QEYhVTJlKp06m3G0VE70LFWa
cBb2HBdrKweJz1t4u+Yvm7PkVOe79rmnAQ6jvmbDOHJ7yYorXX7xVV6AAbInedGp3rHAForpFFnN
zW9oe0xSZgxGqdBij7vI9BaLnqXcLEblsj+trRzMaNM8WEluAKguq/kgi4O1G3V6G+az0sllp5Wt
GJ1K7zGpRwlFhRVTSLn54ZlL0TItLyoXcMlULeU8eZjd/cNX+lOgf/nJVMdUKA4W+qzr6bNKOmhz
5DU3VYhOpQmdMb88i5HVyT8C+gdcOjUQRWkdHDndNr22clSDxeM4tS+3Uy2HtviLU2Q7gnGwNmyu
ye2y9Q7iK1xxI1wJXHzlj04l7ply0x0U8x+CGxI5p0DfR/zEsF8anOuFBI/BGvuktnKwCI9wKc3S
zGF6/6Vo2vOEH4+ivmbDOGIYrQ/mDR7hikuuUh3iMR6d6jJ5E1l0qi+uZd30Yjknf7PwzVvkXELM
Orengj8Y+XVTOsebLA7WVg5aBrO32M77bT006b19YgfJ+gCukthIf2QtWPkBm5ZjX3ykP/R5opZy
5XyoV05q6I9E+yONxpEV4moVpKbmOf4QV7PmayoXjfibRwA5sjU40hjAtYoYB6vq/kEArg1AIEcQ
yBEEcgSx+UCfFe9rVvLbkSN46UQij3MNAv0RBHIEgRxBIEcQyJGGAMohkCPloCkii4f1Z3y5awmS
gQ3iPuRI12+9Z+nPdQP8unK+FL799y1HcjcGQPnP33ARlioLaRpHS2Qxtjr4AlpbZkcAGUWUrwCk
BVHuQjLcRxyxx8i/mxIXfC1NpA4CJGYt6VWS2vw5y6FOXOILHY/qlvIsYUubdfkukqEM7sV1aHxt
Kw+XlDyr0Q0Vz9CEs2zRKt0MnfbJw+NNF3f7lrPi0iuA/IbH5dxQsBg2Rb0Mf+u/lkwmC+4R3fw9
v/Npf5mK9mYLB3twrrmf5hrxt8m/bwTiGgwH9F5gF2+LH972lhMLS5lHMtxHHJGzWUjnhv0yrJdt
UONejnb4hIfpWhZG6bQip7VfLiEZyqAZlHvuNS3e1bb9Qv8ZeetjSzvHAcjfh51HbsQX6R7Fzl//
0ejlZno03zw13jMOnU3a/171SSty+Ph52eVFDrUTUUCf9V73WRH1BV4w0VcRdgFypDJw/r3X72sQ
yBEEcgSBHEEgRxDIEQRyBIFAjiCQI2uFscnlG6sC5AgCxxEEcgSx3sD1I+sym98DwO/erLaDauTY
Wi+8BqgA5xoE+iMI5AgCfVZE4zjw6LOWddlUtlGr9//cMmy7qqKen6jWZtvzM9WqW8BPea0uZxQ5
Urb7yB/7rZoixd5VnaPqiwZup2qx7RU3oNoWGKFXWtYo+iP1vl+u/a7TUOtG7rpaw3Gk7u+cUTNd
jPCDmdXbVqtugVr1C0aOVBwaDPprVO3XF6casl1tUXBL1mi7pJ6aWhBVBjmy8gyvrup6Vmsuqq7Z
9lpbEF0G/ZE6TjXGGmeKtU9z6to9nNIyyJF606n2zwPr9UlivT+RxGdold1Ho/icYVVPJ1ZbtOQB
S60VqKtpfNTzkYgyGJcTsSLxcK5BrATkCAI5gkCOIJAjCOQIotERC93fIxAO1AiO4JMSBEQNGTjX
INAfQSBHEMgRBHIEsYXufSvcBTfqHQ82dNM4Eh5dlrdK8xv3a96bgocFnGsQ6I8gkCNVTallzpbk
MwwvdSOe9xuRlozGa7zb0HL2G6RT66WdWElV2tCu2mY3Xm3sTl39XGMYDvNdJhvsxznjv0J4TiPE
fCebl3v9BpSiJX/TixujcRrPK4ZAYxuoU1c9jkQJSg01eMZ/XFQYu8KeoAh5fUmier+llr2GNUDj
aaUBSw3UqTXONarh/IQGO7VkICwZENWNGyTVSENqcLuJjTdCfVramobo1DpqOVXf92+s3DOqsfHe
SQUfb1MaX4VmqxE6NVbfy5ayfQWFqeH7EpUNJokaaMDWaHwDtGtbzYOGCqEvM6n25tjn7a5Prxol
Q7Oxwo1xQzTeWMsTh/Xs1NgqX4NafjjzznDyBHOqhnuSn1m/uSZUtd8y3XMa0FiNj2xUg3SqT8tp
lI0MvdywH5WFP69p2IaGP69RV3rosflNVst0MmKz3hFo3M+CkSONgUZeKxDNkeWt0rVbJuZ7YQvz
N7bVSI0N3XDg2gAEcgSBHEEgRxDIEQRyBLHV4b/3xS+XQKzAEfxqCQTONQjkCAI5gkCOIJAjCOQI
AjmCQCAQEfh/BtF5XZS2jNwAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-07-09 13:58:47 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASMAAAHsCAIAAAAW/FwbAAAXvUlEQVR42u2dMW4cxxKGFzBgONiA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-07-08 16:11:27 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-06-18 14:44:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-05 15:53:54 +0000" MODIFIED_BY="[Empty name]">Previous search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-05 15:53:56 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Cochrane Schizophrenia Group's trials register (September 2006)</HEADING>
<P>We searched the Cochrane Schizophrenia Group's trials register (September 2006) using the phrase:<BR/>[((fluphen* or flufen* or modec* or moditen* or eutimax* or prolixin* or siqualon* or anaten* or dapotum* or decazate* or decafen* or decentan* or fludecate* or lyogen* or lyoridin* or mirenil*) in title, abstract and index fields in REFERENCE) OR (fluphenazin* in interventions field in STUDY)]</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">group module</A>).</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-07-08 16:11:27 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-06-18 14:44:46 +0100" MODIFIED_BY="[Empty name]">Previous data collection and analysis section</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-08 16:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>1. Selection of trials</B>
<BR/>We (HEM, MQA) independently inspected the citations identified from the search. We identified potentially relevant abstracts and ordered full papers to reassess these for inclusion and methodological quality. We discussed and reported any disagreements.</P>
<P>
<B>2. Assessment of methodological quality</B>
<BR/>We assessed the methodological quality of included trials in this review using the criteria described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). These criteria are based on the evidence of a strong relationship between allocation concealment and direction of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), and define the following categories:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment). For the purpose of the analysis in this review, trials were included if they met the Cochrane Handbook criteria A or B.<BR/>Only trials falling in category A or category B were included in this review.</P>
<P>
<B>3. Data collection</B>
<BR/>3.1 Data extraction<BR/>We (HEM and MQA) independently extracted data and, where further clarification was needed, the authors' of trials were contacted to provide missing data. Any disagreements were discussed and the decisions documented.</P>
<P>3.2 Intention to treat analysis<BR/>Where people were lost to follow-up at the end of the study, it was assumed that they had a poor outcome and once they were randomised they were included in the analysis (intention-to-treat (ITT) analysis).<BR/>
<BR/>
<B>4. Data synthesis</B>
<BR/>4.1 Data types: We assessed outcomes using continuous (e.g. average changes on a behaviour scale), categorical (e.g. one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures, e.g. either 'no important changes' or 'important changes' in a person's behaviour. RevMan software does not currently support categorical data, so we only presented these in the text of the review.</P>
<P>4.2 Dichotomous - yes/no - data<BR/>Where the original authors of the studies gave outcomes such as 'clinically improved' or 'not clinically improved' we recorded this. If possible, we attempted to convert relevant outcome measures to dichotomous data by identifying cut off points on rating scales and dividing people accordingly into 'clinically improved' or 'not clinically improved'. For example, the Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is used frequently as a measure of change of symptoms in studies. We defined a 50% change on this particular scale as clinically important although it was recognised that for many people, especially those with chronic or severe illness, a less rigorous definition of important improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, we used the 50% cut-off for the definition in the case of non-chronically ill people and 25% for those with chronic illness. For dichotomous data we estimated fixed-effect (FE) relative risk (RR) with a 95% confidence interval (CI), and calculated the number needed to treat/harm (NNT/H) statistic. If heterogeneity was found (see section 5) we used a random-effects model.</P>
<P>4.3 Continuous data: We excluded continuous data if more than 50% of people were lost to follow-up. Continuous data were reported as presented in the original studies, without making any assumptions about those lost to follow-up.</P>
<P>4.3.1. Skewed data: Continuous data on mental health outcomes are often not 'normally' distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to all data before inclusion: (a) standard deviations (SD) and means were reported in the paper or were obtainable from the authors, (b) when a scale started from a finite number (such as zero), the SD, when multiplied by two, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution - (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied to them. However, we reported data not meeting these standards in the text of the results section if they had been analysed with appropriate nonparametric tests. Scale-derived change data were reported if no endpoint data were available. Their normality cannot be tested as above, despite the distinct possibility of skew.</P>
<P>4.3.2. Rating scales: a wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore, we only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal. In addition, we set the following minimum standards for instruments: The instrument should either be (a) a self-report or (b) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning.</P>
<P>4.3.3 Summary statistic: For continuous outcomes we estimated the weighted mean difference (WMD) between groups. Again, if heterogeneity was found (see section 5) we used a random-effects model.</P>
<P>4.3.4 Cluster trials: studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra class correlation co-efficients of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation co-efficient (ICC) Design effect = 1+(m-1)*ICC (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>
<B>5. Investigation for heterogeneity</B>
<BR/>We judged clinical heterogeneity within all comparisons between included studies, and visually inspected graphs in order to investigate the possibility of statistical heterogeneity. This was supplemented by the I<SUP>2</SUP> statistic which provides an estimate of the percentage of variability due to heterogeneity rather than to chance alone. An I<SUP>2</SUP> estimate equal to or greater than or equal to 75% indicates the presence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). In such cases, we sought to remove outlying trial(s) and perform a sensitivity analyses both with and without these outlying trials. Where no obvious outlying trial(s) could be identified, we analysed and reported the result using a random-effects model, which takes into account that the effects being estimated are not identical.</P>
<P>
<B>6. Sensitivity analyses</B>
<BR/>We undertook several sensitivity analyses (see: Objectives).</P>
<P>
<B>7. General</B>
<BR/>If possible, we presented data in the graphs so that a result to the left of the line of no effect favoured oral fluphenazine.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;82 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1267 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1267 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1274 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1216 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;41 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;7 studies awaiting assessment&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>